DRUG ADMINISTRATION DEVICE

Abstract

A drug delivery device having a central axis, the drug delivery device comprises: a first body part; a first connecting part attached to the first body part and having a first distal end; a second connecting part having a second distal end and an actuator mechanism configured to move the first distal end towards the second distal end.

Description

This description pertains to a drug delivery device, and in particular to a drug delivery device for oral administration. The drug delivery device is advantageously configured for the administration of an active pharmacological substance into the gastrointestinal system or tract, including the stomach and / or intestines, such as the small and / or large intestine (colon). Background of the Invention A number of, for example, low-permeability and / or low-water-solubility active drug substances are currently administered subcutaneously, intradermally, intramuscularly, rectally, vaginally, or intravenously. Oral administration has the potential for the widest patient acceptance, and therefore, attempts have been made to administer low-permeability and / or low-water-solubility active substances via the preferred oral route, but with limited success, particularly due to instability and limited absorption from the gastrointestinal tract. Stability refers to both the stability of the active pharmaceutical substance during manufacturing and the core ίη / ζζηζ / E / γίΛΐ Ref: 339352 storage of the administration device as to the stability of the active pharmacological substance during passage through the gastrointestinal tract before it is available for absorption. Limited gastrointestinal absorption is due to the gastrointestinal wall barrier preventing the active ingredient from being absorbed after oral dosing due to the low permeability of the active ingredient, which is due, for example, to pre-systemic metabolism, size and / or charges and / or due to the water solubility of the active drug substance. Multiple procedures have been suggested to solve these stability and absorption challenges, but an effective solution to the challenges remains elusive. Brief Description of the Invention Therefore, there is an unmet need for a drug delivery device capable of administering pharmacological substances for absorption into the gastrointestinal tract. More generally, there remains a need for pharmaceuticals and methods that enable improved drug delivery when pharmaceuticals are administered orally to patients. A drug delivery device is described, for example, for oral drug delivery. The drug delivery device has a central axis and comprises a first body part; a first connecting part attached to the first body part and having a first distal end; a second connecting part having a second distal end; and an actuator mechanism optionally configured to move, such as rotate, the first distal end toward the second distal end. A pharmaceutical composition comprising an active pharmacological substance and one or more delivery devices as described herein is also described. It is an advantage of the present description that the drug delivery device ensures the stability of the active ingredient during passage through the gastrointestinal system or tract and facilitates the efficient absorption of the active ingredient from the gastrointestinal tract after oral administration. Furthermore, it is an advantage of the present description that the drug delivery device provides an active attachment of the drug delivery device to the gastrointestinal wall, such as the stomach wall and / or intestinal wall. Furthermore, the present description advantageously provides for the oral administration of active pharmacological substances of low permeability in or to the gastrointestinal tissue. Brief Description of the Figures The foregoing and other features and advantages of the present invention will become readily apparent to those skilled in the art through the following detailed description of exemplary embodiments thereof with reference to the accompanying figures, in which: Figure 1 shows an exploded view of an example drug delivery device, Figure 2 shows a cross-sectional side view of an example drug delivery device, Figure 3 shows a perspective view of an example drug delivery device, Figure 4 shows a perspective view of an example of a drug delivery device, Figure 5 shows a front view of an example drug delivery device, Figure 6 shows a side view of an example of a drug delivery device, Figure 7 shows a front view of an exemplary drug delivery device coupled with a biological material; Figure 8 shows an encapsulated drug delivery device, Figure 9 shows an orderly exploded view of an example drug delivery device having rotating joining parts, Figure 10 shows a perspective view of an example Ln / zznz / E / YiAi core drug delivery device, Figures 11A-11D show a schematic view of the operation of the drug delivery device, Figure 12 shows a drug delivery device in a first state, Figure 13 shows a drug delivery device in a second state, Figure 14 shows a drug delivery device in a first state, Figure 15 shows a drug delivery device in a second state, Figure 16 shows a drug delivery device, Figure 17 shows the drug delivery device of Figure 16 in an orderly exploded view, Figures 18-22 show experimental results using a drug delivery device and Figure 23 shows pharmacodynamic data using a drug delivery device. Detailed Description of the Invention The following describes several examples of embodiments and details, with reference to the figures where appropriate. It should be noted that the figures may or may not be drawn to scale and that elements of similar structures or functions are represented by similar core reference numbers Ln / zznz / E / YiAi throughout the figures. It should also be noted that the figures are intended only to facilitate the description of the embodiments and their associated functionalities. They are not intended to be an exhaustive description of the invention or a limitation of the scope of the invention or its physical appearance. Furthermore, an illustrated embodiment does not necessarily have all the features or advantages shown. A feature or advantage described in conjunction with a particular embodiment is not necessarily limited to that embodiment and may be implemented in any other embodiment, even if it is not explicitly illustrated or described. A drug delivery device having a central axis is described. The drug delivery device comprises a first body part; a first connecting part; a second connecting part; and an actuator mechanism configured to move the first connecting part and the second connecting part relative to each other, for example, by moving, such as rotating, the first body part relative to a second body part. The drug delivery device may have a size and geometry designed to fit a pharmaceutical composition for oral administration. The drug delivery device / pharmaceutical composition can be configured for oral insertion. Therefore, its external dimensions can be small enough for a user to swallow it. The drug delivery device can be adapted to deliver a pharmaceutical substance to the user's body via the digestive system, such that it can travel, for example, from the user's mouth to the stomach via the esophagus. From the stomach, the drug delivery device can then travel further into the intestines and, optionally, be expelled through the rectum. The drug delivery device can be configured to deliver medication anywhere in the user's digestive system. For example, it can be configured to deliver a pharmaceutical substance directly into the user's stomach. Alternatively, it can be adapted to initiate drug delivery once the device has passed through the stomach and entered the user's intestine. In other words, the drug delivery device can be configured to attach to a stomach wall or an intestinal wall, depending on the desired release position of the drug's active ingredient. The attachment portion(s) of the drug delivery device can be configured to interact with the internal surface linings of the gastrointestinal tract, such that the device can, for example, attach to the internal surface (mucous membrane) of the stomach or, alternatively, to the mucous membrane of the intestines. The attachment portion(s) can also be configured to interact with mucous membranes, for example, to fix or attach the drug delivery device, for example, for a period of time, within the user's body. Connecting the drug delivery device allows a drug substance to be administered to a part of the digestive system, thus providing the user with the drug.The connecting part or parts can be configured to interact with mucous membranes, for example, to inject a pharmacological substance into the wall of the gastrointestinal tract. The drug delivery device has a central shaft that optionally extends from a first end to a second end. The length of the drug delivery device (e.g., the greatest extension from the first end to the second end along the central shaft) may be in the range of 3 mm to 35 mm, or in the range of 5 mm to 26 mm. The drug delivery device may be lengthened. The drug delivery device may have a width and / or height (e.g., the largest extensions along the width axis and the height axis, respectively) in the range of 1 mm to 20 mm. The height and width are the largest extensions of the drug delivery device perpendicular to the central axis. In one or more exemplary drug delivery devices, the dimensions of the drug delivery device, at least in an initial or first state before the actuation of the first connecting part and / or the second connecting part, may be represented by a length (greatest extent along the central axis), a width (greatest extent along the width axis perpendicular to the central axis), and a height (greatest extent along the height axis perpendicular to both the central and width axes). The height of the drug delivery device may be in the range of 1 mm to 15 mm. The width of the drug delivery device may be in the range of 1 mm to 15 mm. In one or more example drug delivery devices, the drug delivery device can be constructed in such a way as to ensure the drug delivery part delivers a payload or active drug substance into the internal tissue or internal surface for distribution of the active drug substance in the subject through the blood vessels. Advantageously, the drug delivery device can be attached and can deliver the active drug ingredient to a specific location within a patient's intestinal wall. Of course, the delivery device can also be attached and can deliver the active drug substance to other locations. In one or more exemplary drug delivery devices, the drug delivery device, such as the spike, can penetrate the muscularis mucosa. In one or more exemplary drug delivery devices, the drug delivery device, such as the spike, may not penetrate the outer muscular layer. In one or more exemplary drug delivery devices, the spike can be placed in the submucosa. In one or more exemplary drug delivery devices, the spike can be placed in the submucosa parallel to the intestinal wall. The drug delivery device comprises a first body part. The first body part may be a two-part body part, that is, the first body part may comprise a primary first body part and a secondary first body part. The first body part has an external surface. A primary first recess and / or a secondary first recess may be formed on the external surface of the first body part. The drug delivery device optionally comprises a cover having a first cover portion. An outer surface of the first body portion may constitute at least a portion of the first cover portion. The drug delivery device comprises a first connecting part. The first connecting part may comprise a first base part and / or a first needle, for example, a spike. The first connecting part has a first proximal end and a first distal end. The first connecting part, such as the first needle or spike, optionally has or extends along a first connecting axis. A first tip of the first needle forms the first distal end. In other words, the first distal end is a first tip of the first needle. The first base may be disposed on or constitute the first proximal end of the first connecting part. The first needle may have a length in the range of 1 mm to 15 mm, such as in the range of 3 mm to 10 mm. Thus, sufficient penetration into the internal tissue can be provided while at the same time reducing the risk of damaging the internal tissue.The first distal end of the first joining part may be provided with a tip configured to penetrate biological tissue. The first distal end of the first joining part core ίη / ζζηζ / E / γίΛΐ may be provided with a gripping portion configured to grasp biological tissue. The first needle can have a cross-sectional diameter in the range of 0.1 mm to 5 mm, such as in the range of 0.5 mm to 2.0 mm. The first needle may be straight and / or curved. The first needle may comprise a first primary section that is straight. The first needle may comprise a first secondary section, for example, between the first primary section and the first distal end or between the first base and the first primary section. The first secondary section may be curved. The first needle may include two or more straight portions formed at an angle. For example, the first needle may have a proximal portion extending at a first angle from a point of connection to the drug delivery device and a distal portion extending at a second angle from a point of connection to the drug delivery device. The first and second angles may be different. The proximal portion may connect to the distal portion at a joint (e.g., bend, connection, angle) and have a joining angle between the proximal and distal portions.The joint angle can be acute, obtuse, or right. For example, the angle can be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, or 170 degrees. This can advantageously allow for different joint angles when the first needle interacts with the inner surface coatings. This can enable improved bonding of the drug delivery device while helping to reduce or prevent tissue damage. Furthermore, the joint can be flexible. Alternatively, the joint can be inflexible. The joint can be located at a center, or generally at the center, of the first needle length. Alternatively, the joint can be located at 40, 45, 55, 60, or 65% along the first needle from the proximal end. In one or more exemplary first joining parts, the first needle may have three, four, or five different portions at different angles, each connected by a joint. In some iterations, any or all of the different portions may be straight or curved. Each joint may be flexible or inflexible. The attachment parts of a drug delivery device can be viewed as any type of attachment that can connect the drug delivery device to a biological tissue, such as the stomach wall, intestinal wall, and / or intestines of a human or animal body. The attachment parts can be adapted to extend away from the central axis of the drug delivery device and / or the central axis of the first attachment part. This may mean that the attachment part(s), for example, at least in an activated state or in a second state of the drug delivery device, can extend away from a peripheral surface (in a radial direction) of the first attachment part and / or the second attachment part, such that the attachment part extends further radially than the peripheral or external surface of the attachment part. The first joining part can be fixed or rotatably attached to the first body part. In one or more exemplary drug delivery devices, the drug delivery device comprises a second body part. The second body part may be a two-part body part, that is, the second body part may comprise a main second body part and a secondary second body part. The connecting second part is optionally attached to the second body part. The connecting second part may be fixedly or rotatably attached to the second body part. The second body part has an external surface. A main second recess and / or a secondary second recess may be formed on the external surface of the second body part. In one or more exemplary drug delivery devices, the actuator mechanism is configured to rotate the first body part relative to the second body part around a principal axis of the drug delivery device. The principal axis may be parallel to and / or coincide with the central axis. In one or more exemplary drug delivery devices, the first body part is configured to rotate in a first direction and / or the second body part is configured to rotate in a second direction opposite to the first direction. The drug delivery device may comprise a frame portion to which various parts, such as the first body portion and / or the second body portion, are attached, for example, either fixedly or rotatably to the frame portion. In one or more exemplary drug delivery devices, the actuator mechanism or parts thereof may be attached to the frame portion. Therefore, separate rotation of the first body portion and the second body portion relative to the frame portion may be provided. The rotating connection between the first body part and the second body part allows the first body part to rotate relative to the second body part without the two parts separating before the joining part or parts interact with internal tissue, such as mucous membranes. Such a connection can be achieved in a plurality of ways, where, in one example, the first body part has a male plug connection and the second body part has a receptacle connection, where this male plug and receptacle configuration allows the first body part to rotate relative to the second body part.A second example could be providing a shaft that can be coaxial with the central and / or primary shaft, wherein the first and second body parts are configured to receive the shaft, and a stop device is disposed at the first and second ends of the shaft, on each side of the combined first and second body parts, preventing the first and second body parts from sliding longitudinally along the shaft. The shaft can be integrated into either the first or second body part. If a shaft is used, it can be made from any number of different materials. For example, the shaft can be made from metals, alloys, polymers, composites, or combinations thereof. The first and / or second body parts can be arranged to rotate freely relative to each other, at least in the second position, thus allowing the connecting parts to rotate. Therefore, the connecting parts can be adapted to contact and / or penetrate the tissue of the gastrointestinal tract. Rotating the body parts relative to each other using an elastic force can move the connecting parts so that they can, for example, penetrate or pinch the mucous membrane to secure the drug delivery device in a location within the gastrointestinal system, such as the stomach or intestines. The penetration and / or pinching force can originate from the actuator / elastic part mechanism, where the elastic part can be adapted to store an elastic force capable of forcing the connecting parts together when the elastic force of the elastic part has been at least partially released.The elastic part can be, for example, in the form of a spring or spring element, such as a torsion spring or a force spring, where the spring can be coiled to store mechanical energy, which can then be transmitted to the first and / or second body part. When the mechanical energy is released, the first body part can rotate relative to the second body part, and the mechanical energy can be transferred to the connecting parts via the body parts. Within the context of this description, the term rotational force can be understood as torque, moment, moment of force, rotational force, or twisting effect. Another definition of rotational force is the product of the magnitude of the force and the perpendicular distance of the line of action of the force from the axis of rotation. Rotational force can be seen as the force transferred from the elastic component to the connecting elements of the drug delivery device via the body parts. Rotational force can be defined as sufficiently large to penetrate gastrointestinal tissue. When rotational force is applied to both the first and second body parts, the first attachment element may come into contact with the surface to which it is to be attached, and the rotational force applied to the second body part may cause the second attachment part to come into contact with the same surface. The first attachment part exerts a force, while the second attachment part exerts a force opposite to the first, such that the force is applied in such a way that the first attachment part is forced in one direction towards the second attachment part, or vice versa. In one or more exemplary drug delivery devices, the distance between the first bonding axis of the first bonding part and the primary axis, for example, at least in an activated or second state of the drug delivery device and optionally in an initial state of the drug delivery device, is greater than 0.5 mm. core Ln / zznz / E / YiAi In one or more exemplary drug delivery devices, the distance between the second axis of the second bonding part and the main axis, for example, at least in an activated or second state of the drug delivery device and optionally in an initial state of the drug delivery device, is greater than 0.5 mm. In one or more examples of drug delivery devices, the first connecting part is rotatably attached to the first body part, for example, via a first connecting link having a first axis of rotation. In other words, the first connecting part is optionally configured to rotate about a first axis of rotation, for example, relative to the first body part. The first axis of rotation may be parallel to the central axis and / or the primary axis. The first axis of rotation may form a first angle with the central axis and / or the primary axis. The first angle may be less than 15°. The first angle may be in the range of 75° to 105°, such as 90° ± 5° or 90°. In one or more exemplary drug delivery devices, the first body part may define a first body recess (e.g., a cavity, groove, or hole) extending to an external surface of the first body part. The first body recess may be formed by solid walls on all sides except for one external surface, which is open. The first connecting part may be rotatably connected within the first body recess along a first connecting part axis. The first connecting part axis may be, for example, a bolt (e.g., arm, bracket). The first connecting part axis may be parallel to the center axis and / or the main axis. The first connecting part axis may be angled with respect to the center axis and / or the main axis. Consequently, the first connecting part may be configured to rotate within the recess along the first connecting part axis.Furthermore, the rotation of the first joining part can be stopped at the extreme surfaces of the rebate. The first body rebate may extend along a portion of the outer surface of the first body. The first body rebate may extend completely along an outer circumference of the first body. The first body rebate may extend approximately 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of an outer circumference of the first body. The first body rebate may extend approximately more than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of an outer circumference of the first body. The first body rebate can extend around less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of an external circumference of the first body. The first body can optionally contain more than one first body rebate; for example, a plurality of first joining parts are used in the first body.If more than one first body rebate is used, they may be spaced longitudinally and / or circumferentially. The first body recess may extend from an external surface to the central axis through 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The first body recess may extend from an external surface to the central axis through more than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The first body recess may extend from an external surface to the central axis through less than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. In one or more exemplary drug delivery devices, the first body recess may extend circumferentially or partially circumferentially around the first body, with the central axis being the longitudinal direction. The first body recess may extend perpendicularly to the central axis and / or the main access point (for example, it may extend along a cross-section of the drug delivery device perpendicular to the central axis and / or the main access point). The first body recess may have any number of shapes. For example, the first body recess may be a portion of a circle, such as a semicircle. The first body recess may be a triangle. The first body recess may be a sector of a circle. The first body recess may be a curved edge connected by two straight edges.The first body rebate may consist of two curved edges connected to each other by two straight edges. Thus, the first joining part can rotate on its axis to move perpendicularly to the central axis and / or the main axis. In certain embodiments, the first joining part can rotate at an angle between perpendicular and parallel with respect to the central axis and / or the main axis. In one or more exemplary drug delivery devices, when the first body part and / or the second body part rotate relative to each other, the first connecting part and / or the second connecting part may rotate out of their respective recesses (e.g., first body recess and second body recess) due to the rotation of the first body part and / or the second body part. The continued rotation of the first body part and / or the second body part then causes the first connecting part and / or the second connecting part to pierce the tissue to retain the drug delivery device in place. In one or more examples of drug delivery devices, the first connecting portion extends, for example, at least in an activated state of the drug delivery device and optionally in an initial state of the drug delivery device, in a direction away from the first body part. In other words, the first needle may extend, for example, at least in an activated state of the drug delivery device and optionally in an initial state, from an external surface of the first body part. Alternatively, the first connecting shaft may, for example, at least in an activated state of the drug delivery device and optionally in an initial state of the drug delivery device, form an angle of at least 45° with the central axis and / or the main axis.A joining part that extends in one direction should be understood as the direction from the proximal end of the joining part / needle part to the distal end of the joining part along the joining axis of the joining part. The first connecting portion can extend in a first state of the drug delivery device in a first primary direction and in a second state of the drug delivery device in a first secondary direction. The first primary direction and the first secondary direction can form an angle of at least 30°. The first primary direction can be parallel or substantially parallel to the central axis. The first primary direction can form an angle of less than 60° with the central axis. The first secondary direction can form an angle of at least 60°, such as approximately 90°, with the central axis. The first secondary direction can be perpendicular to the central axis. The first distal end of the first joining part can be configured to move or be moved from a first primary position in a first state of the drug delivery device to a first secondary position in the second state. The drug delivery device comprises a second connecting part. The second connecting part may comprise a second base and / or a second needle, for example, a spike. The second connecting part has a second proximal end and a second distal end. The second connecting part, such as the second needle, optionally has or extends along a second connecting axis. A second tip of the second needle forms the second distal end. In other words, the second distal end is a second tip of the second needle. The second base may be arranged on or constitute the second proximal end of the second connecting part. The second needle may have a length in the range of 1 mm to 15 mm, such as in the range of 3 mm to 10 mm. Therefore, sufficient penetration into the internal tissue can be provided while at the same time reducing the risk of damaging the internal tissue.The second distal end of the second joining part may be provided with a tip configured to penetrate biological tissue. The second distal end of the second joining part may be provided with a gripping portion configured to grasp biological tissue. The second needle can have a cross-sectional diameter in the range of 0.1 mm to 5 mm, such as in the range of 0.5 mm to 2.0 mm. The second needle may be straight and / or curved. The second needle may comprise a second primary section that is straight. The second needle may comprise a second secondary section, for example, between the second primary section and the second distal end or between the second base and the second primary section. The second secondary section may be curved. The second needle may include two or more straight portions formed at an angle. For example, the second needle may have a proximal portion extending at a first angle from a point of connection to the drug delivery device and a distal portion extending at a second angle from a point of connection to the drug delivery device. The first and second angles may be different. The proximal portion may connect to the distal portion at a joint (e.g., bend, connection, angle) and have a joint angle between the proximal and distal portions. The joint angle may be an acute angle, an obtuse angle, or a right angle. The angle can be, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160 or 170 degrees.This can advantageously allow for different joint angles when the second needle interacts with internal surface coatings. This can enable improved bonding of the drug delivery device while helping to reduce or prevent tissue damage. Additionally, the joint can be flexible. Alternatively, the joint can be inflexible. The joint can be located at a center, or generally at the center, one needle length away. Alternatively, the joint can be located at 40, 45, 55, 60, or 65% of one needle length away from the proximal end. In one or more exemplary second-part joints, the second needle may have three, four, or five different portions at different angles, each connected by a joint. In some iterations, any or all of the different portions may be straight or curved. Each joint may be flexible or inflexible. In one or more exemplary drug delivery devices, both the first and second needles include a joint. However, only one of the first and second needles may include a joint with the other, which may be straight and / or curved. If both the first and second needles include a joint, the first distal tip and the second distal tip may be angled toward each other to facilitate joining when the first and second body portions rotate relative to each other. In one or more examples of drug delivery devices, the second connecting part is rotatably attached to the second body part, for example, via a second connecting link that has a second axis of rotation. In other words, the second connecting part is optionally configured to rotate around a second axis of rotation, for example, relative to the second body part. The second axis of rotation may be parallel to the central axis and / or the main axis. The second axis of rotation may form a second angle with the central axis and / or the main axis. The second angle may be less than 15°. The second angle may be in the range of 75° to 105°, such as 90° ± 5° or 90°. In one or more exemplary drug delivery devices, the second body part may define a second body recess (e.g., cavity, slot, hole) extending to an external surface of the second body part. The second body recess may be formed by solid walls on all sides except for one external surface, which is open. The second connecting part may be rotationally connected within the second body recess along a second connecting part axis. The second connecting part axis may be, for example, a bolt (e.g., arm, bracket). The second connecting part axis may be parallel to the central axis and / or the main axis. The second connecting part axis may be angular with respect to the central axis and / or the main axis. Consequently, the second connecting part may be configured to rotate within the recess along the second connecting part axis.Furthermore, the rotation of the second joining part can be stopped at the extreme surfaces of the second body recess. The second body rebate can extend along a portion of the second body's outer surface. The second body rebate can extend completely along an outer circumference of the second body. The second body rebate can extend approximately 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of the second body's outer circumference. The second body rebate can extend approximately more than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of the second body's outer circumference. The second body rebate can extend around less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of an external circumference of the second body. The second body can optionally contain more than one second body rebate; for example, a plurality of second joining parts are used in the second body.If more than one second body rebate is used, they may be spaced longitudinally and / or circumferentially. The second body recess may extend from an external surface toward the central axis through 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The second body recess may extend from an external surface toward the central axis through more than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. The second body recess may extend from an external surface toward the central axis through less than 5, 10, 15, 20, 25, 30, 35, or 40% of the drug delivery device. In one or more exemplary drug delivery devices, the second body recess may extend circumferentially or partially circumferentially around the second body, with the central axis being the longitudinal direction. The second body recess may extend perpendicularly to the central axis and / or the main access point (for example, it may extend along a cross-section of the drug delivery device perpendicular to the central axis and / or the main access point). The second body recess may have any number of shapes. For example, the second body recess may be a portion of a circle, such as a semicircle. The second body recess may be a triangle. The second body recess may be a sector of a circle. The second body recess may be a curved edge connected by two straight edges.The second body rebate may consist of two curved edges connected to each other by two straight edges. Thus, the second connecting part can rotate about its own axis to move perpendicularly to the central axis and / or the main axis. In certain configurations, the second connecting part can rotate at an angle between perpendicular and parallel with respect to the central axis and / or the main axis. In one or more exemplary drug delivery devices, when the first body part and / or the second body part rotate relative to each other, the first joining part and / or the second joining part may rotate out of their respective recesses (e.g., first body recess and second body recess) due to the rotation of the first body part and / or the second body part. The continued rotation of the first body part and / or the second body part then causes the first joining part and / or the second joining part to pierce the tissue to retain the drug delivery device in place. In one or more examples of drug delivery devices, the second connecting part extends, for example, at least in an activated state of the drug delivery device and optionally in an initial state of the drug delivery device, in a direction optionally away from the second body part. In other words, the second needle can extend, for example, at least in an activated state of the drug delivery device and optionally in an initial state, from an external surface of the second body part. Alternatively, the second connecting axis can, for example, at least in an activated state of the drug delivery device and optionally in an initial state of the drug delivery device, form an angle of at least 45° with the central axis and / or the main axis. The second connecting portion can extend in a first state of the drug delivery device in a second primary direction and in a second state of the drug delivery device in a second secondary direction. The second primary direction and the second secondary direction can form an angle of at least 30°. The second primary direction can be parallel to or substantially parallel to the central axis. The second primary direction can form an angle of less than 60° with the central axis. The second secondary direction can form an angle of at least 60°, such as approximately 90°, with the central axis. The second secondary direction can be perpendicular to the central axis. The second distal end of the second part of the connection can be configured to move or be moved from a second primary position in a first state of the drug delivery device to a second secondary position in the second state. The drug delivery device comprises an actuator mechanism. The actuator mechanism is configured to move the first connecting part relative to the second connecting part, such as moving the first distal end toward and / or away from the second distal end, for example, at least during part of a rotation, such as in a first rotation and optionally in a second rotation. Moving the first distal end toward the second distal end can be understood as reducing the distance between the first distal end and the second distal end. Moving the first distal end toward the second distal end can be understood as reducing an angle between the first connecting axis and the second connecting axis, such as reducing an angle between a first secondary direction of the first connecting part and a second secondary direction of the second connecting part.In one or more exemplary drug delivery devices, the actuator mechanism is configured to move the first distal end toward the second distal end by rotating, for example, in a second state of the drug delivery device, the first body part relative to the second body part and / or vice versa. The actuator mechanism may be configured to rotate the first body part at least 90°, such as at least 450°, at least 810°, at least 1170°, at least 1530°, or even at least 1890° relative to the second body part around the main axis. The actuator mechanism may be configured to rotate the first body part relative to the second body part around the main axis in a stepped or gradual manner.In other words, rotating the first body part relative to the second body part around the main axis can comprise a plurality of rotations, including a first rotation and a second rotation. For example, a first rotation followed by a first period of time with reduced rotation or no rotation followed by a second rotation. A first rotation followed by a second rotation after a first period of time can increase the likelihood of the drug delivery device adhering to the biological tissue. The first period of time, or, more generally, the periods of time between rotations, allows the drug delivery device to move to other positions in the gastrointestinal tract. In other words, if the drug delivery device does not adhere to the biological tissue during a first rotation, subsequent rotations increase the likelihood of it adhering to the internal tissue.The first rotation may be at least 90° and the second rotation may be at least 180°. The plurality of rotations may include a third rotation. The third rotation may be at least 180°. In one or more exemplary drug delivery devices, the movement of the first distal end toward the second distal end may be preceded and / or followed by a movement of the first distal end away from the second distal end. In other words, the movement of the first distal end toward the second distal end may occur before and / or after the movement of the first distal end away from the second distal end. For example, a first rotation may comprise moving the first distal end toward the second distal end and / or moving the first distal end away from the second distal end. For example, a second rotation may comprise moving the first distal end toward the second distal end and / or moving the first distal end away from the second distal end.For example, a third rotation may involve moving the first distal end towards the second distal end and / or moving the first distal end away from the second distal end. The actuator mechanism optionally comprises a resilient or elastic part, such as a spring element configured to apply force to the first body part and / or the second body part. The elastic part may comprise a first part, such as a first end, connected to the first body part. The elastic part may also comprise a second part, such as a second end, connected to the second body part. In one or more exemplary drug delivery devices, the actuator mechanism optionally comprises an expansion means, i.e., a means that increases its volume, for example, upon contact with a fluid, to allow rotation of the parts relative to each other. In one or more exemplary drug delivery devices, an inflatable means provides rotation of the first connecting part relative to the first body part and / or provides rotation of the second connecting part relative to the second body part. In one or more exemplary drug delivery devices, an inflatable means provides rotation of the first body part relative to the second body part. The actuator mechanism, such as the elastic part, can be configured to rotate the first joining part around the first axis of rotation relative to the first body part. The actuator mechanism, such as the elastic part, can be configured to rotate the second joining part around the second axis of rotation relative to the second body part. In one or more exemplary drug delivery devices, the drug delivery device comprises a first compartment. The drug delivery device is configured to deliver an active drug substance from the first compartment to the surrounding area of ​​the drug delivery device. The first compartment may be disposed in the first connecting part, such as the first needle, for example, within a distance of 8 mm, such as within 5 mm, from the first distal end. The first connecting part, such as the first needle, may have one or more openings providing access to the first compartment. In one or more exemplary drug delivery devices, the first compartment is formed as a through-hole in the first needle. The first compartment can be arranged anywhere within the drug delivery device, such as in the form of a cavity within a volume of the first body part, the second body part, or both. Additionally or alternatively, the first compartment can be a core compartment located within the first binding part, where penetration of the first binding part into a biological tissue can release a drug substance into the biological tissue.Additionally or alternatively, the first compartment may be a compartment that has the form of a depression or opening or spike or hollow spike on the external surface of the first and / or second body part, where the drug delivery device can be adapted to release the pharmacological substance into the body organ through which the drug delivery device is adapted. In one or more exemplary drug delivery devices, the first compartment may be open from an internal volume of the drug delivery device to an external part of the device. In one or more examples, the first compartment may be located within the first body part and be in fluid communication with the first connecting part, such that when the first distal end of the first connecting part has penetrated the biological tissue, the drug substance can be released from the first compartment into the biological tissue via the first connecting part. This may be, for example, when the first connecting part is a tubular part having a first distal end core in fluid communication with the first compartment of the drug delivery device. In one or more exemplary drug delivery devices, the drug delivery device comprises a second compartment. The drug delivery device is configured to deliver an active drug substance from the second compartment to the surrounding area of ​​the drug delivery device. The second compartment may be disposed in the first connecting portion or the second connecting portion, such as the second needle, for example, within 8 mm or 5 mm from the second distal end. The second connecting portion, such as the second needle, may have one or more openings providing access to the second compartment. In one or more exemplary drug delivery devices, the second compartment is formed as a through-hole in the first or second needle. In one or more exemplary drug delivery devices, the first and second junction portions form an angle when the first distal end and the second distal end lie in a plane that includes the principal axis. In other words, the first and second junction portions may form an angle, for example, greater than 5°, such as in the range of 10° to 75°, when the first and second distal ends lie in a plane that includes the primary Ln / zznz / E / YiAi core axis. In one or more exemplary drug delivery devices, the drug delivery device has a first state, also called the initial state, in which the first body part and the second body part are rotatably stationary relative to each other, and a second state, also called the activated state, in which the first body part and the second body part are rotatably movable relative to each other, for example, they can rotate around the main axis of the drug delivery device. In other words, the first body part can be locked, for example, prevented from rotating, relative to the second body part. The first state can be, for example, an initial or insertion state, in which the drug delivery device is adapted for insertion into the body and in which the first body part and the second body part are stationary relative to each other.In the first state, the elastic part can have a predefined amount of stored energy, where the energy level is stationary in the elastic part while the body parts are stationary. In one or more exemplary drug delivery devices, the device has a first state in which the elastic portion carries a constant elastic force load, and a second state in which the elastic portion releases at least partially the elastic force load. In other words, the elastic portion can be deflected or preloaded in the first drug delivery state, and upon release, for example, by the release of a locking mechanism (i.e., the drug delivery device being in the second state), the force of the elastic portion can effect a rotation of the first body part with respect to the second body part, that is, a movement from the first distal end to the second distal end. In one or more exemplary drug delivery devices, the actuator mechanism is configured to move the first distal end from a first primary position, for example, in the first state of the drug delivery device, with a first primary radial distance from a central axis of the delivery device to a first secondary position, for example, in the second state of the drug delivery device, with a first secondary radial distance from the central and / or primary axis, wherein the first secondary radial distance is greater than the first primary radial distance.Therefore, the first distal end of the first joining part may be in a first primary position when the drug delivery device is in the first state and / or the first distal end of the first joining part may be in a first secondary position when the drug delivery device is in the second state. The first primary radial distance may be less than 10 mm, such as less than 8 mm or even less than 5 mm. The first secondary radial distance may be greater than the first primary radial distance. The first secondary radial distance may be greater than 5 mm, such as greater than 6 mm or greater than 8 mm. In one or more exemplary drug delivery devices, the first secondary radial distance is in the range of 6 mm to 15 mm. In one or more exemplary drug delivery devices, the first connecting part, such as a portion of the first needle and / or the first distal end, may, in the first state, be disposed or at least partially disposed within a first main recess of the first body part. In the first state, the first distal end may be disposed within the first body part. In one or more exemplary drug delivery devices, the first joining part, such as a part of the first needle and / or the first distal end, may, in the second state, be disposed or at least partially disposed outside the first main recess of the first body part. In one or more examples of drug delivery devices, the first connecting part, such as a portion of the first needle and / or the first distal end, can be arranged in the first state within a second main recess of the second body part. Therefore, the first connecting part can be configured to lock the first body part relative to the second body part in the first state of the drug delivery device. In one or more examples of drug delivery devices, the first joining part, such as a part of the first needle and / or the first distal end, may, in the second state, be disposed outside of the second body part and / or at least outside of the second main recess of the second body part. In one or more exemplary drug delivery devices, the actuator mechanism is configured to move the second distal end from a second primary position, for example, in the first state of the drug delivery device, with a second primary radial distance from a central axis of the central delivery device to a second secondary position, for example, in the second state of the drug delivery device, with a second secondary radial distance from the central axis and / or the primary axis, wherein the second secondary radial distance is greater than the second primary radial distance.Therefore, the second distal end of the second part of the connection may be in a second primary position when the drug delivery device is in the first state and / or the second distal end of the second part of the connection may be in a second secondary position when the drug delivery device is in the second state. The second primary radial distance may be less than 10 mm, such as less than 8 mm or even less than 5 mm. The second secondary radial distance may be greater than the second primary radial distance. The second secondary radial distance may be greater than 5 mm, such as greater than 6 mm or greater than 8 mm. In one or more exemplary drug delivery devices, the second secondary radial distance is in the range of 6 mm to 15 mm. In one or more exemplary drug delivery devices, the second connecting part, such as a portion of the second needle and / or the second distal end, may, in the first state, be disposed or at least partially disposed within a first secondary recess of the first body part. Therefore, the second connecting part may be configured to lock the first body part relative to the second body part in the first state of the drug delivery device. In the first state, the second distal end may be disposed within the second body part. In one or more examples of core Ln / zznz / E / YiAi drug delivery devices, the second joining part, such as a part of the second needle and / or the second distal end, may, in the second state, be disposed or at least partially disposed outside the first body part and / or at least outside the first secondary recess of the first body part. In one or more examples of drug delivery devices, the second joining part, such as a second needle part and / or the second distal end, may be disposed in the first state within a second secondary recess of the second body part. In one or more examples of drug delivery devices, the second joining part, such as a second needle part and / or the second distal end, may be disposed in the second state outside the second secondary recess of the second body part. In one or more exemplary drug delivery devices, the actuator mechanism is configured to move, for example, by rotation about a first axis of rotation of the first connecting part (first base part), the first distal end from a first primary angular position of the first primary position to a first secondary angular position of the first secondary position relative to a first proximal end of the first connecting part. The angle between the first primary angular position and the first secondary angular position may be greater than 10°, such as greater than 45° or greater than 60°. In one or more exemplary drug delivery devices, the actuator mechanism is configured to move, for example, by rotation around a second axis of rotation of the second connecting part (second base part), the second distal end from a second primary angular position of the second primary position to a second secondary angular position of a second secondary position relative to a second proximal end of the second connecting part. The angle between the second primary angular position and the second secondary angular position may be greater than 10°, such as greater than 45° or greater than 60°. In one or more exemplary drug delivery devices, the drug delivery device comprises a locking mechanism. The locking mechanism can be configured to, for example, prevent the rotation of the first body part relative to the second body part in a first state of the drug delivery device. The locking mechanism can also be configured to lock the first connecting part in a first primary position, for example, relative to the first body part, when the drug delivery device is in the first state. Upon release of the locking mechanism, the first connecting part can be allowed to move from a first primary position to a first secondary position.The locking mechanism can be configured, after release, to allow rotation of the first body part relative to the second body part, for example, in a second state of the drug delivery device. The locking mechanism can be configured to lock the second connecting part in a second primary position, for example, relative to the second body part, when the drug delivery device is in the first state. The locking mechanism can be configured, after release, to allow the second connecting part to move from a second primary position to a second secondary position. The locking mechanism may comprise a first locking element optionally configured to lock and / or unlock (release) the first body part with respect to the second body part. The first locking element may be configured to lock and / or unlock (release) the first joining part with respect to the first body part. The first locking element may be configured to lock and / or unlock (release) the second joining part with respect to the second body part. The first locking element may be arranged in a first main recess of the first body part and / or in a second main recess of the second body part.The first locking element can be configured to dissolve when the drug delivery device enters the gastrointestinal tract or a desired location within the gastrointestinal tract, thereby releasing the first body part relative to the second body part and allowing the actuator mechanism to rotate the first body part relative to the second body part and thus move the first distal end towards the second distal end, resulting in the attachment of the drug delivery device to the internal tissue. The first locking element can be a first locking band (e.g., ring, loop, partial ring, partial loop). The first locking band can have a circumferential length greater than its longitudinal width. For example, the circumferential length can be 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x the longitudinal width. The first locking band can be attached to an external surface of the drug delivery device. For example, the first locking band can be placed on an external surface of the first body part or the second body part. The first locking band can be mechanically attached to the drug delivery device. For example, the first locking band can be press-fitted onto the drug delivery device. The first locking band can also be chemically bonded to the drug delivery device. In one or more exemplary drug delivery devices, the first locking band could be in the form of a capsule portion. For example, the first locking band could form the first half of a capsule. Alternatively, the first locking band could form the first half of a capsule, and a second locking band could form the second half. When fitted together, the first locking band and the second locking band could form a complete capsule. The first locking band can partially or completely cover the first body rebate if it is located on the first body. Therefore, the first locking band can prevent movement of the first joining part. The first locking band can partially or completely cover the second body rebate if it is located on the second body. Therefore, the first locking band can prevent movement of the second joining part. The first locking band can partially or completely cover both the first and second body rebate. The first locking band can partially or completely cover the first body rebate, and a second locking band can partially or completely cover the second body rebate. The first locking band can extend completely around an outer circumference of the drug delivery device. The first locking band can extend approximately 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of an outer circumference of the drug delivery device. The first locking band can extend approximately more than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of an outer circumference of the drug delivery device. The first blocking band can be extended around less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% of an external circumference of the drug delivery device. In one or more exemplary drug delivery devices, the first locking band may include one or more locking protrusions (e.g., extensions, tabs, fingers, projections, teeth). For example, the first locking band may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 locking protrusions. The locking protrusions may extend longitudinally from only one side of the first locking band. The locking protrusions may extend longitudinally from both sides of the first locking band. The locking protrusions may be equally spaced along the first locking band. The locking protrusions may be unevenly spaced along the first locking band. One or more locking protrusions can extend towards a longitudinal center of the drug delivery device (e.g., along an external body surface towards the second body part, if the first locking band is located on the first body part, or along an external body surface towards the first body part, if the first locking band is located on the second body part). The one or more locking protrusions may be triangular, square, rectangular, rounded, or polygonal in shape. The one or more locking protrusions may vary in shape along the first locking band. In one or more exemplary drug delivery devices, the drug delivery device may include mating features. Mating features may be configured to mate with one or more protrusions of the first locking band. Mating features may include one or more mating protrusions (e.g., extensions, tabs, fingers, projections, teeth) that extend radially outward from an external surface of the drug delivery device. Mating features may extend from the first body part, the second body part, or both. Mating features may be formed in one or more circumferential rows. For example, there may be one circumferential row of mating features or two circumferential rows of mating features.Both circumferential rows can be in the same body part (for example, the first body part or the second body part). In alternative implementations, one circumferential row of coupling features can be in the first body part and a second circumferential row of coupling features can be in the second body part. The one or more mating protrusions may be triangular, square, rectangular, rounded, or other polygonal shapes. The one or more mating protrusions may vary in shape along the first locking band. The one or more mating protrusions may be angled in a circumferential direction to form a mating recess (e.g., curve, cavity, space, gap). This mating recess helps lock one or more mating protrusions with one or more protrusions of the first locking band. Furthermore, the mating recess prevents unintended release of the first locking band. Consequently, when the first locking band attaches to the drug delivery device, the one or more locking protrusions can fit between one or more mating protrusions.One or more locking lugs can fit inside adjacent mating lugs. This can prevent the first body from rotating relative to the second body. For example, the first locking lug will prevent the first body from rotating. In some embodiments, the locking lug can be located between two mating lugs, each angled in opposite directions to hold the locking lug in place. In some implementations, the mating features may be recesses that extend internally into the drug delivery device. The locking protrusions may then extend radially inward instead of longitudinally to engage with these mating features. As discussed above, when the first locking band is joined and one or more protrusions engage with the mating features, the first body part is locked in place relative to the second body part. The first and second body parts can be released from the first locking band when the first locking band dissolves as described herein. Furthermore, dissolving the first locking band can allow the first or second joining part to rotate further away from the first or second body recess. Therefore, when the first and second bodies rotate relative to each other, the first and second joining parts can rotate to insert into the tissue. In one or more exemplary drug delivery devices, the first locking band may include one or more square locking protrusions and / or one or more triangular locking protrusions. The square locking protrusions can be used to hold the cover in place under the force of the mating protrusions. The triangular locking protrusions can be used to properly position the first locking band. In one or more examples of drug delivery systems, the entire first locking band may dissolve. In one or more examples of drug delivery systems, only the square locking protrusions may be formed from a soluble material. Once the square locking protrusions dissolve, the first body part and the second body part may be allowed to rotate. Rotation of the first body part relative to the second body part may cause the first locking band to shift, for example, move, change position, or relocate. This can occur because the coupling protrusions may squeeze the triangular locking protrusions, pushing them longitudinally outward. For example, rotation may cause the first locking band to shift along the central axis. This translation may expose the first binding portion and / or the second binding portion, depending on the coverage of the first locking band. The translation may completely displace the first locking band from the drug delivery device. The translation may partially displace the first locking band to expose the first binding portion and / or the second binding portion, with the first locking band remaining associated with, for example, the drug delivery device. The locking mechanism may include a second locking element optionally configured to lock and / or unlock (release) the first body part with respect to the second body part. The second locking element may be configured to lock and / or unlock (release) the second joining part with respect to the second body part. The second locking element may be arranged in a first secondary recess of the first body part and / or in a second secondary recess of the second body part.The second locking element can be configured to dissolve when the drug delivery device enters the gastrointestinal tract, thereby unlocking or releasing the first body part relative to the second body part and allowing the actuator mechanism to rotate the first body part relative to the second body part and thus allowing the first distal end to move towards the second distal end resulting in the attachment of the drug delivery device to the internal tissue. One or more exemplary drug delivery devices may include a first cover band (e.g., ring, loop, partial ring, partial loop). The first cover band may be used in conjunction with the first locking element, e.g., locking element, locking mechanism. In one or more exemplary drug delivery devices, the first cover band may be the first locking band. In one or more exemplary drug delivery devices, the first cover band may include any or all of the features discussed above with respect to the first locking band. The first cover band may have a circumferential length greater than its longitudinal width. For example, the circumferential length may be 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x the longitudinal width. The first cover strip can be fitted onto an external surface of the drug delivery device. For example, the first cover strip can be located on an external surface of the first body part or the second body part. In one or more exemplary drug delivery devices, the first cover strip could be in the form of a capsule portion. For example, the first cover strip could form the first half of a capsule. Alternatively, the first cover strip could form the first half of a capsule, and a second cover strip could form the second half. When fitted together, the first cover strip and the second cover strip could form a complete capsule. The first cover strip can be mechanically attached to the drug delivery device. For example, the first cover strip can be pressed onto the drug delivery device. The first cover strip can also be chemically bonded to the drug delivery device. The first cover strip may partially or completely cover the first body rebate if it is located on the first body. Therefore, the first cover strip may prevent movement of the first joining part. The first cover strip may partially or completely cover the second body rebate if it is located on the second body. Therefore, the first cover strip may prevent movement of the second joining part. The first cover strip may partially or completely cover both the first and second body rebate. The first cover strip may partially or completely cover the first body rebate, and a second cover strip may partially or completely cover the second body rebate. The first cover band can extend completely around an outer circumference of the drug delivery device. The first cover band can extend approximately 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% of an outer circumference of the drug delivery device. The first cover band can extend approximately more than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% of an outer circumference of the drug delivery device. The first cover band can extend around less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% of an outer circumference of the drug delivery device. In one or more exemplary drug delivery devices, the first cover band may include one or more mating protrusions (e.g., extensions, tabs, fingers, projections, teeth). For example, the first cover band may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mating protrusions or projections. The mating protrusions may extend longitudinally from only one side of the first cover band. The mating protrusions may extend longitudinally from both sides of the first cover band. The mating protrusions may be equally spaced along the first cover band. The mating protrusions may be unevenly spaced along the first cover band. One or more coupling protrusions can extend towards a longitudinal center of the drug delivery device (e.g., along an external body surface towards the second body part if the first cover band is located on the first body part or along an external body surface towards the first body part if the first cover band is located on the second body part). In one or more exemplary drug delivery devices, the drug delivery device may include docking features. The docking features may be configured to engage, for example, receive, grasp, or contact one or more docking protrusions on the first cover band. The mating features may include one or more body-coupling protrusions (e.g., extensions, tabs, fingers, projections, teeth) that extend radially outward from an external surface of the drug delivery device. The mating features may extend from the first body part, the second body part, or both. The mating features may be formed in one or more circumferential rows. For example, there may be one circumferential row of mating features or two circumferential rows of mating features. Both circumferential rows may be on the same body part (e.g., the first body part or the second body part).In alternative implementations, a circumferential row of coupling features may be in the first body part and a second circumferential row of coupling features may be in the second body part. The one or more mating protrusions may be triangular, square, rectangular, rounded, or other polygonal shapes. The one or more mating protrusions may vary in shape along the first cover band. The one or more mating protrusions may be angled in a circumferential direction to form a mating recess (e.g., curve, cavity, space, gap). This mating recess may help fit one or more mating protrusions of the body into one or more protrusions of the first cover band. In addition, the mating recess may prevent unintentional release of the first cover band. Consequently, when the first cover band attaches to the drug delivery device, one or more mating protrusions can fit between one or more mating features. The mating protrusions can also fit within adjacent mating features. This can help to properly align the first cover band. In some implementations, the mating features may be recesses that extend internally into the drug delivery device. The mating protrusions may then extend radially inward rather than longitudinally to match the mating features. In one or more exemplary drug delivery devices, rotation of the first body part relative to the second body part may cause the cover strip to translate—for example, to move, change position, or relocate. For instance, rotation may cause the cover strip to translate along the central axis. This translation may expose the first bonding part and / or the second bonding part, depending on the cover strip's coverage.This can occur, for example, because mating protrusions can squeeze triangular or other mating protrusions, pushing them longitudinally outward. Translation can completely dislodge the cover strip from the drug delivery device. Translation can partially dislodge the cover strip to expose the first and / or second mating portions of the cover strip, which is attached to the drug delivery device. In one or more exemplary drug delivery devices, the first cover strip can be dissolved. Dissolving the first cover strip allows the first or second locking part to rotate further outward from the first or second body recess. Therefore, as the first and second bodies rotate relative to each other, the first and second locking parts can rotate to insert into the tissue. The material and / or properties of the first and / or second locking element can be selected so that the release of the body parts and / or the activation of the drug delivery device are controlled to occur at a desired location in the gastrointestinal tract, such as the stomach or intestines.The material of the first locking element and / or the second locking element may comprise one or more sugars, sugar derivatives, hydrophilic polymers, pH-dependent polymers, and pharmaceutically acceptable excipients that disperse, dissolve, swell, and / or gel upon contact with water / fluid. In one or more exemplary drug delivery devices, at least part of the first bonding part and / or the second bonding part may be made of a biodegradable, absorbable, or similar material that allows the bonding part material to decompose, degrade, and / or dissolve through processes present in the body, such as corrosion, degradation, hydrolysis, and / or proteolytic enzymatic degradation. Therefore, when the bonding part(s) have been inside the human body for a period of time, they may dissolve, decompose, or degrade to such an extent that they lose their structural stability, which may in turn release the drug delivery device from the surface to which it has adhered.Therefore, after a period, for example, when the drug has been released from the binding part or parts, the binding part or parts may deteriorate to such a degree that the drug delivery device can be released and can continue its journey through the gastrointestinal tract to be released through the user's or patient's natural bowel and / or intestinal movements. In one or more examples of drug delivery devices, the axis of rotation of the first body part and / or the second body part (main axis) may be the central axis of the drug delivery device; for example, the main axis of the first body part may be coaxial with the central axis. Therefore, the central axis intersects both the first and second body parts and may define the primary axis. In one or more exemplary drug delivery devices, the first body part and the second body part may be substantially symmetrical in a radial direction perpendicular to the central axis. This may mean that the first body part and / or the second body part may have a circular periphery, where the periphery may extend radially away from and perpendicular to the central axis. The first joining axis can be viewed as an axis coaxial with the length of the first joining part. The second joining axis can be viewed as an axis coaxial with the length of the second joining part. If the first joining part is not straight, the first joining axis can be defined as an axis intersecting the first distal end and the first proximal end of the first joining part. If the second joining part is not straight, the second joining axis can be defined as an axis intersecting the second distal end and the second proximal end of the second joining part. In one or more exemplary drug delivery devices, the first attachment axis can be placed at a first distance from the central axis, while the second attachment axis can be located at a second distance from the central and / or main axis. For example, the first connecting axis can be positioned at a first principal distance from the central axis in the first state of the drug delivery device. The first principal distance can be greater than 0.5 mm, such as in the range of 1 mm to 15 mm, or greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm. The first joining axis may cross or be close (distance less than 0.5 mm) to the central axis in the first state of the drug delivery device. The first connecting axis can be positioned at a first secondary distance from the central axis in the second state of the drug delivery device. The first secondary distance can be greater than 0.5 mm, such as in the range of 1 mm to 15 mm, or greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm. The first connecting axis may cross or be close (distance less than 0.5 mm) to the central axis in the second state of the drug delivery device. For example, the second connecting axis can be positioned at a second principal distance from the central axis in the first state of the drug delivery device. The second principal distance can be greater than 0.5 mm, such as in the range of 1 mm to 15 mm, or greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm. The second attachment axis may cross or be close (distance less than 0.5 mm) to the central axis in the first state of the drug delivery device. The second attachment point can be positioned at a second secondary distance from the central axis in the second state of the drug delivery device. This second secondary distance can be greater than 0.5 mm, such as in the range of 1 mm to 15 mm, or greater than 1 mm, for example, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, or 14 mm. The second connecting axis may cross or be close (distance less than 0.5 mm) to the central axis in the second state of the drug delivery device. core ίη / ζζηζ / Ε / γίΛΐ In one or more exemplary drug delivery devices, the first connecting part (first connecting axis) and / or the second connecting part (second connecting axis) may be configured to form an angle with each other where they intersect a plane that includes the central axis. The plane may be a plane containing the central axis, wherein the plane also includes a radial axis extending at a right angle to the central axis. Where the first connecting part intersects the plane, the first connecting axis of the first connecting part may be at an angle to the plane, such that the first distal end of the first connecting part is the first portion of the first connecting part that intersects the plane, wherein the remaining portions of the first connecting part subsequently intersect the plane during rotational movement.The second joining part may intersect the same plane from the opposite side, where the second distal end of the second joining part is the first part of the second joining part to intersect the plane, and the remaining parts of the second joining part intersect the plane subsequently during the rotational movement. Therefore, the second joining part optionally intersects the plane from a rotational direction opposite to that of the first joining part. This can also mean that when the first distal end and the second distal end of the respective first joining part and second joining parts each make contact with the plane, the first joining part (first joining axis) is at an angle to the plane, as well as at an angle to the second joining part (second joining axis).The angle between the first joining part (first joining axis) and the second joining part (second joining axis) with the plane can be approximately half the angle between the first joining part and the second joining part. In one or more exemplary drug delivery devices, the first body part may be configured to rotate in a first direction and the second body part may be configured to rotate in a second direction, where the first direction is opposite to the second direction. Thus, as an example, the first body part may rotate clockwise, while the second body part may rotate counterclockwise. In one or more examples where the drug delivery device comprises three or more body parts, adjacent or neighboring body parts may rotate in opposite directions. This may also mean that every other body part may rotate in the same direction.For example, when a first body part and a third body part rotate in the same first direction, then a second body part and / or a fourth body part can rotate in a second direction opposite to the first direction. In one or more exemplary drug delivery devices, the actuator mechanism may comprise one or more elastic parts, such as a plurality of elastic parts. In one or more exemplary drug delivery devices, the first distal end of the first connecting part and / or the second distal end of the second connecting part may be provided with a sharp point configured to penetrate biological tissue. The sharp point may be positioned near the distal end of the respective connecting part, and the sharp point may be configured to have a diameter at the distal end that is smaller than the diameter of the connecting part at a distance from the distal end. The sharp point may be configured such that when a rotational force is applied to the first connecting part and a counterforce is applied to the second connecting part, the counterforce causes the sharp point to penetrate the biological tissue due to the force applied by the actuator mechanism. When the first and / or second attachment portions penetrate the biological tissue due to rotation between the first and second attachment portions (the first distal end moves towards the second distal end), the respective points of penetration in the biological tissue can be used to deliver a drug substance from the drug delivery device to the biological tissue. This allows the drug substance to be introduced into the biological tissue beyond the mucosal core membrane. Therefore, the drug substance can enter the bloodstream more easily than if it were released in the stomach or intestinal lumen, and drug delivery can be more effective.An example of this is when the drug substance is insulin, where the insulin can be degraded within the gastrointestinal tract and is not able to be absorbed from the gastrointestinal tract, but where a mucous membrane has been penetrated and the insulin released through the gastrointestinal wall penetrated, the insulin will remain intact and reach the user's bloodstream via the blood vessels in the intestinal layer beyond the (surface of) mucous membrane. In one or more exemplary drug delivery devices, the first and / or second attachment portions may be provided with a gripping portion configured to grasp biological tissue. The gripping portion can be used to enhance traction between the attachment portion and a mucous membrane, enabling the attachment portion to secure the drug delivery device within the user's body. The gripping portion may be a part that increases mechanical friction between the attachment portion and the surface to which it is to be attached, wherein the gripping portion may be, for example, hook-shaped or, for example, a shape in which the gripping portion of the first attachment portion is oriented toward the gripping portion of the second attachment portion, such that the biological tissue placed between the first and second attachment portions is held between the two gripping or holding portions. In one or more exemplary drug delivery devices, a portion of the elastic part can be connected to the first body part, and a second portion of the elastic part can be connected to the second body part. This means that the elastic part can be used to store energy, such as rotational energy or rotational force, applied to the first and second body parts, where the energy is stored in the elastic part. Furthermore, when the energy is released, for example, when a locking element dissolves or degrades, the force can be released in both the first and second body parts, which in turn transfer the force to the first and second connecting parts.The elastic portion can be, for example, in the form of a helical coil spring (main spring) and / or a spiral torsion spring, where the first body portion can be wound around the second body portion by rotating the first body portion relative to the second body portion. This stores energy in the main spring by rotating the coil more tightly. The stored force of the main spring can then rotate the first body portion in the opposite direction as the main spring unwinds. Thus, the force of the main spring can cause the first and second attachment portions to move in opposite directions, and the attachment portions can pinch or penetrate the biological tissue to bind the drug delivery device to the biological tissue. Once the drug delivery device has entered the body, for example, the desired part of the gastrointestinal tract, it can be configured to transform from the first state to the second state. This transformation can be initiated by various means. For instance, the first and second body parts can be held in the first state using a locking mechanism. This mechanism might comprise one or more locking elements made of a soluble, expandable, or degradable material. The material reacts with the environment, such as fluids, within the desired body part, thereby unlocking or releasing the locking mechanism. The locking element material can be one that loses its structural strength upon contact with the environment within the desired body part.An example of this is when the locking element(s) are made of a polymeric material or a sugary substance that can dissolve, expand, or degrade upon contact with a certain type of fluid, such as an enzyme or acid, within the digestive system. When the locking element comes into contact with the reagent, the material can dissolve, expand, or degrade over time. When the rotational force of the drug delivery device exceeds the static force of the locking element, the rotational force can be released by rotating the first body part relative to the second body part, or vice versa. In one or more exemplary drug delivery devices, a locking element can fix a connecting part in a position where the locking element blocks the first body part relative to the second body part, that is, it prevents the first body part from rotating relative to the second body part. When the locking element dissolves or degrades, the connecting part can be moved to a secondary position where it no longer blocks the first body part relative to the second, for example, by an actuator mechanism that causes the connecting part to rotate about an axis of rotation relative to the body part to which it is rotatably attached. The second state of the drug delivery device can be viewed as the state initiated by the release of energy stored in the actuator mechanism, for example, the elastic parts of the actuator mechanism, resulting in a rotational force of the first and / or second body part and / or a rotational force of the first attachment part relative to the first body part. The termination of the second state can be seen as a point in time where the energy stored in the elastic part returns to a stationary state; that is, when the attachment parts have grasped or penetrated the biological tissue and / or the rotational movement between the first and second body parts ceases. In one or more exemplary drug delivery devices, the device may have a first state where the actuator mechanism has a constant elastic force load and a second state where the actuator mechanism releases the elastic force load. In the first state, the constant elastic force load can be viewed as the energy stored in the actuator mechanism, and the elastic force load is greater than zero. The second state can be viewed as a state where the actuator mechanism releases its elastic force load, where the elastic force load decreases, for example, approaching zero, by rotating the first body part relative to the second body part. The second state may end when the connecting parts come into contact with or penetrate biological tissue, and the elastic force load remains unchanged, even though it has not reached zero.Therefore, a third state can follow the second state, when the drug delivery device has attached to a wall of biological material and the elastic force load is stationary after an elastic force release. The first and / or second connecting parts may have a deployable function, whereby, during the first state of the drug delivery device (i.e., the initial state of the drug delivery device), the connecting parts are positioned or arranged within the first and / or second body parts. Alternatively, the first and / or second connecting parts may be folded along the sides of the body parts. Other methods of achieving the same result may be considered. The folded state (first state) may be maintained, for example, by using a releasable locking mechanism in the form of an encapsulation similar to a drug capsule, a band, or a plug, for example, made of gelatin, sugars, or other soluble materials, or materials that lose their structural strength.Therefore, the connecting parts can be held in place until the drug delivery device has entered the gastrointestinal tract, for example, the stomach, in such a way that the connecting parts do not interfere with or damage the lining of the mouth and / or esophagus. Before or during the transition to the second state, the connecting parts can be extended from the body parts outward, making them ready to interact with the lining of the digestive system. When the connecting part(s) are in a folded or bent position, the distance from the central axis to the distal end of the connecting part is greater in the second state than in the first state. Therefore, the diameter of the drug delivery device in the first state will be smaller than the diameter of the drug delivery device in the second state. In one or more exemplary drug delivery devices, at least part of the first joining part and / or the second joining part, such as the first needle and / or the second needle, may be manufactured from a material comprising one or more of magnesium, titanium, iron, and zinc, which allows for exact and precise control of the size and / or shape / geometry of the first joining part and / or the second joining part, which in turn allows a delivery device to have the desired joining capabilities and / or small production variations, which is particularly important in the pharmaceutical industry. The first connecting part, such as the first needle, may be made of a material comprising one or more of magnesium, titanium, iron, and zinc. The material of the first connecting part / first needle may be biocompatible and / or biodegradable. The material of the first connecting part / first needle may comprise one or more biodegradable polymers such as PLA and / or POLGA. Some, part, most, substantially all, or all of the material of the first connecting part / first needle may be biocompatible and / or biodegradable. The material of the first connecting part, such as the first needle, may comprise, consist of, or consist essentially of biocompatible and / or biodegradable material, such as biocompatible and / or biodegradable metals.The first bonding part material, such as the first needle, may comprise a biodegradable or bioresorbable metal or metal alloy, such as magnesium, zinc, and / or iron, or an alloy comprising one or more of magnesium, zinc, and iron. A biodegradable or bioresorbable metal or metal alloy may be understood as a metal or metal alloy that safely degrades within, for example, a human body within a practical amount of time, for example, in relation to its application. The first bonding part material, such as the first needle, may comprise one or more metals, such as a combination of one or more metals, for example, a metal alloy. The second connecting part, such as the second needle, may be made of a material comprising one or more of magnesium, titanium, iron, and zinc. The material of the second connecting part / second needle may be biocompatible and / or biodegradable. The material of the second connecting part / second needle may comprise one or more biodegradable polymers such as PLA and / or POLGA. Some, part, most, substantially all, or all of the material of the second connecting part / second needle may be biocompatible and / or biodegradable. The material of the second connecting part, such as the second needle, may comprise, consist of, or consist essentially of biocompatible and / or biodegradable material, such as biocompatible and / or biodegradable metals.The second joining material, such as the second needle, may comprise a biodegradable or bioresorbable metal or metal alloy, such as magnesium, zinc, and / or iron, or an alloy comprising one or more of magnesium, zinc, and iron. A biodegradable or bioresorbable metal or metal alloy may be understood as a metal or metal alloy that safely degrades within, for example, a human body within a practical timeframe, for example, relative to its application. The second joining material, such as the second needle, may comprise one or more metals, such as a combination of one or more metals, for example, a metal alloy. One advantage of having a biodegradable material used in the attachment part(s) may be that the delivery device can deliver an active drug substance or payload disposed in the attachment part(s) and / or body parts of the delivery device to a specific part of the subject's body, for example, such as the stomach or intestines, after the delivery device has adhered to the internal surface, for example, the intestinal wall, thanks to the sharp properties of the attachment part(s) material and for a prolonged period of time, as the biodegradable material will gradually degrade over time.Furthermore, when the material of the binding part(s) is biodegradable, the binding part(s) will degrade in the human body and disappear after the active pharmaceutical ingredient (API) contained in the drug delivery device has been administered, thus preventing long-term harm to the human body. The binding part(s) can be configured to degrade over a period of hours (e.g., 2, 5, 10, 20, or 24 hours), days (e.g., 1, 2, or 5 days), or weeks (e.g., 1, 2, 3, or 5 weeks). The material of the connecting part or parts, such as the needle or needles, may comprise one or more, or a combination of, magnesium (Mg), zinc (Zn), and / or iron (Fe). An advantage of having the connecting part or parts made of a material comprising Mg, Zn, and / or Fe may be that the shape and size of the connecting part or parts can be precisely controlled, thereby providing better adhesion to the internal surface, for example, to an inner wall of the intestines of a human subject. For example, the material of the joining part or parts, such as the needle or needles, may comprise 0.001% to 100% by weight of biodegradable metal, such as 0.001% to 100% by weight of magnesium, 0.001% to 100% by weight of zinc, 0.001% to 100% by weight of iron. The material of the joining part or parts, such as the needle or needles, may comprise, for example, 0.001% by weight of Mg, 0.005% by weight of Mg, 0.01% by weight of Mg, 0.05% by weight of Mg, 0.1% by weight of Mg, 0.5% by weight of Mg, 1% by weight of Mg, 5% by weight of Mg, 10% by weight of Mg, 20% by weight of Mg, 30% by weight of Mg, 40% by weight of Mg, 50% by weight of Mg, 60% by weight of Mg, 70% by weight of Mg, 80% by weight of Mg, 90% by weight of Mg or 100% by weight of Mg. The material of the joining part or parts, such as the needle or needles, may comprise, for example, 0.001% by weight of Zn, 0.005% by weight of Zn, 0.01% by weight of Zn, 0.05% by weight of Zn, 0.1% by weight of Zn, 0.5% by weight of Zn, 1% by weight of Zn, 5% by weight of Zn, 10% by weight of Zn, 20% by weight of Zn, 30% by weight of Zn, 40% by weight of Zn, 50% by weight of Zn, 60% by weight of Zn, 70% by weight of Zn, 80% by weight of Zn, 90% by weight of Zn or 100% by weight of Zn. The material of the joining part or parts, such as the needle or needles, may comprise, for example, 0.001% by weight of Fe, 0.005% by weight of Fe, 0.01% by weight of Fe, 0.05% by weight of Fe, 0.1% by weight of Fe, 0.5% by weight of Fe, 1% by weight of Fe, 5% by weight of Fe, 10% by weight of Fe, 20% by weight of Fe, 30% by weight of Fe, 40% by weight of Fe, 50% by weight of Fe, 60% by weight of Fe, 70% by weight of Fe, 80% by weight of Fe, 90% by weight of Fe or 100% by weight of Fe. The material of the joining part or parts, such as the needle or needles, may comprise a metal alloy such as Zn-Mg, Zn-Fe, Mg-Fe or Zn-Mg-Fe. The material of the joining part or parts, such as the needle or needles, may comprise, for example, a Zn-Mg alloy with 0.001 wt% Mg, 0.005 wt% Mg, 0.01 wt% Mg, 0.05 wt% Mg, 0.1 wt% Mg, 0.5 wt% Mg, 1 wt% Mg, 5 wt% Mg, 10 wt% Mg, 20 wt% Mg, 30 wt% Mg, 40 wt% Mg, 50 wt% Mg, 60 wt% Mg, 70 wt% Mg, 80 wt% Mg or 90 wt% Mg. The material of the joining part or parts, such as the needle or needles, may comprise, for example, a Zn-Fe alloy with 0.001 wt% Fe, 0.005 wt% Fe, 0.01 wt% Fe, 0.05 wt% Fe, 0.1 wt% Fe, 0.5 wt% Fe, 1 wt% Fe, 5 wt% Fe, 10 wt% Fe, 20 wt% Fe, 30 wt% Fe, 40 wt% Fe, 50% by weight of Fe, 60% by weight of Fe, 70% by weight of Fe, 80% by weight of Fe or 90% by weight of Fe. The material of the joining part or parts, such as the needle or needles, may comprise, for example, a Mg-Fe alloy with 0.001 wt% Fe, 0.005 wt% Fe, 0.01 wt% Fe, 0.05 wt% Fe, 0.1 wt% Fe, 0.5 wt% Fe, 1 wt% Fe, 5 wt% Fe, 10 wt% Fe, 20 wt% Fe, 30 wt% Fe, 40 wt% Fe, 50 wt% Fe, 60 wt% Fe, 70 wt% Fe, 80 wt% Fe or 90 wt% Fe. The material of the joining part or parts, such as the needle or needles, may comprise, for example, a Zn-Mg-Fe alloy with 0.001 wt% Fe, 0.005 wt% Fe, 0.01 wt% Fe, 0.05 wt% Fe, 0.1 wt% Fe, 0.5 wt% Fe, 1 wt% Fe, 5 wt% Fe, 10 wt% Fe, 20 wt% Fe, 30 wt% Fe, 40 wt% Fe, 50 wt% Fe, 60 wt% Fe, 70 wt% Fe, 80 wt% Fe, 90 wt% Fe, 0.001 wt% Mg, 0.005 wt% Mg, 0.01 wt% Mg, 0.05 wt% Mg, 0.1% by weight of Mg, 0.5% by weight of Mg, 1% by weight of Mg, 5% by weight of Mg, 10% by weight of Mg, 20% by weight of Mg, 30% by weight of Mg, 40% by weight of Mg, 50% by weight of Mg, 60% by weight of Mg, 70% by weight of Mg, 80% by weight of Mg, 90% by weight of Mg, 0.001% by weight of Zn, 0.005% by weight of Zn, 0.01% by weight of Zn, 0.05% by weight of Zn, 0.1% by weight of Zn, 0.5% by weight of Zn core Ln / zznz / E / YiAi, 1% by weight of Zn, 5% by weight of Zn, 10% by weight of Zn, 20% by weight of Zn, 30% by weight of Zn, 40% by weight of Zn, 50% by weight of Zn, 60% by weight of Zn, 70% by weight of Zn, 80% by weight of Zn or 90% by weight of Zn. The connecting part(s), such as the needle(s), may be made of a material comprising one or more thermoplastic or thermoset polymers. The material of the connecting part(s), such as the needle(s), may comprise one or more active pharmaceutical ingredients (APIs). Therefore, an API may be embedded in the material of the connecting part(s), such as the needle(s), to form a pharmaceutical composition. In some embodiments, the connecting part(s), such as the needle(s), may comprise, for example, water-soluble, water-insoluble, biodegradable, non-biodegradable, and / or pH-dependent soluble materials. In some embodiments, the connecting part(s), such as the needle(s), may comprise a water-soluble, biodegradable, and / or pH-dependent material that can be dissolved and / or degraded such that the connecting part(s), such as the needle(s), lodged in the intestinal tissue can be gradually degraded and / or dissolved. In some embodiments, the connecting part(s), such as the needle(s), may comprise a water-soluble material to allow for the immediate or modified release of the active ingredient, depending on the material selected.In some embodiments, a biodegradable or water-insoluble material may allow the active drug substance to be deposited in the binding portion(s), such as the needle(s), for a longer duration of release (e.g., days, weeks, or months). In some embodiments, a pH-dependent soluble material may allow the binding portion(s), such as the needle(s), to remain intact under sub-physiological pH conditions, e.g., a pH of approximately 7.4, to remain intact in the gastrointestinal lumen, but then dissolve once inside the gastrointestinal wall.In some embodiments, one or more water-soluble, water-insoluble, biodegradable and / or pH-dependent materials can be optionally combined to control the release of the active drug substance, for example, by diffusion or erosion of the binding part or parts, such as the needle or needles, for the duration of the controlled release (for example, minutes, hours, days, weeks, or months). In some embodiments, the connecting part(s), such as the needle(s), may be made of different compositions. For example, an outer portion of the connecting part(s), such as the needle(s), may be made of one composition, and an inner core of the connecting part(s), such as the needle(s), may be made of another composition. In some embodiments, the outer portion and the inner core of the connecting part(s), such as the needle(s), may be composed of, for example, a water-soluble material, a water-insoluble material, a biodegradable material, and / or a pH-dependent material.In some modalities, one or more water-soluble, water-insoluble, biodegradable and / or pH-dependent materials can be combined to control the release of the active drug substance, once the binding part or parts, such as the needle or needles, can be moved from its position in the lumen to the internal tissue, e.g., from the gastrointestinal lumen to the gastrointestinal tissue. In some embodiments, the connecting portion(s), such as the needle(s), may be tubular and may include a tubular body. The tubular body may comprise an active pharmaceutical substance, for example, a liquid payload comprising the active pharmaceutical substance, optionally connected to a tubular connecting portion, such that the payload containing the active pharmaceutical substance can flow through the connecting portion(s), such as the needle(s), into the internal tissue, for example, the intestinal tissue. In some embodiments, the tubular body may contain expandable excipients, such as excipients that can be expanded by a chemical reaction, for example, when mixed, expanding in volume and / or producing a gas to advance the delivery of the payload. In some embodiments, the expansion is by osmosis. In some embodiments, the first compartment (compartment for containing the active drug substance) may comprise a closure portion for sealing the first compartment. The closure portion may contribute to improved control of the release of the active drug substance. In some embodiments, the closure portion may be composed, for example, of a water-soluble, water-insoluble, biodegradable, and / or pH-dependent material. In some embodiments, one or more water-soluble, water-insoluble, biodegradable, and / or pH-dependent materials may be combined to control the release of the active drug substance from the first compartment once the connecting portion(s), such as the needle(s), moves from the lumen to the internal tissue, for example, from the gastrointestinal lumen to the gastrointestinal tissue. Figure 1 shows an exploded view of a drug delivery device 2 according to the description, wherein the drug delivery device comprises a first body part 4, having a first end 6 and a second end 8, and a second body part 10 having a first end 12 and a second end 14. When assembled, the first body part 4 is rotatably connected to the second body part 10, wherein the first end 6 of the first body part rests on the first end 12 of the second body part when connected. The drug delivery device 2 further comprises an actuator mechanism 16 comprising a resilient or elastic part 16A, in this example in the form of a spiral torsion spring. A first part 18 of the elastic part 16A (first end of the spiral torsion spring) is positioned on an outer periphery 22 of the spiral torsion spring, and a second part 20 of the elastic part 16A (second end of the spiral torsion spring) is located in a central part 24 of the spiral torsion spring. The first body part 4 comprises an internal volume 26, wherein the internal volume is adapted to receive the elastic part 16A, and wherein an internal surface 28 of the internal volume 26 comprises one or more first coupling parts 30 configured to couple with the first part 18 of the elastic part 16A, and wherein the first coupling parts can maintain the position of the first part during rotational movement of the first body part 4 and the second body part 10 relative to each other. The second part 20 of the elastic part 16A is configured to couple with a second coupling part 32 (see Figure 2) that is centrally located within the second body part 10. The second coupling part 32, as seen in Figure 2, is configured to extend toward the central part 24 of the spring when the spring is placed within the internal volume 26 of the first body part 4.The second coupling part 32 comprises a groove or slot 34 that is adapted to couple with the second part 20 of the elastic part 16A, such that the rotational movement of the first 4 and / or second body part 10 can wind the elastic part 16A, when the first part 18 is coupled with the first coupling part 30. The drug delivery device 2 has a central axis A, which extends in one direction from the second end 8 of the first body part 4 (first end of the drug delivery device) to the second end 14 of the second body part (second end of the drug delivery device). It can be seen that the central axis A defines the principal axis around which the first body part 4 and the second body part 10 rotate. The first coupling part 30 and the first part 18 of the elastic part 16A may have a coupling, meaning that when the load on the spring exceeds a predefined level, the first end releases the first coupling part 30 and engages with the next coupling part 30'. This means that the drug delivery device may have a torque limiter, where the torque limiter ensures that the energy stored within the elastic element 16 cannot exceed a predefined limit. The drug delivery device 2 comprises a first connecting part 36 having a first proximal end 38 and a first distal end 40. The first connecting part 36 comprises a first straight needle 37 and is fixedly attached to the first body part 4. The first connecting part 36 extends along a first connecting axis, see Figure 2, from an external surface 42 of the first body part 4 in a direction away from the external surface 42. The first distal end 40 of the first connecting part 36 can be a sharp point to allow penetration of biological tissue, wherein the rotational force provided by the elastic element 16A can be used to penetrate body tissue, see also Figure 7. The drug delivery device 2 comprises a second connecting part 44 having a second proximal end 46 and a second distal end 48. The second connecting part 44 comprises a second straight needle 45 and is fixedly attached to the first body part 4. The second connecting part 44 extends along a second connecting axis, see Figure 2, from an external surface 50 of the second body part 10 in a direction away from the external surface 50. The second distal end 48 of the second connecting part 44 can be a sharp point to allow penetration of biological tissue, wherein the rotational force provided by the elastic element 16A can be used to penetrate body tissue, see also Figure 7. The distal ends 40, 48 of the connecting parts 36, 44 may be a sharp point 52, wherein the sharp point 52 may be similar to the sharp point of a hypodermic needle, and wherein the sharp point 52 is capable of penetrating body tissue, such as a mucous membrane of the intestine, stomach, bowels, or other parts of the digestive and / or gastrointestinal system. The needles 37, 45 may be hollow with an opening 56 at the distal ends 40, 48, such that an active pharmacological substance may be introduced via the opening 56 into body tissue after the connecting parts 36, 44 have penetrated the biological tissue, as shown in Figure 7. The elastic force of elastic part 16A is used to rotate the first body part in a first direction B and the second body part in a second direction C around the central axis A, which is the main axis, as seen in Figures 1 and 2 and shown in more detail in Figures 11A-11D. In other words, the actuator mechanism 16 (elastic part 16A) is configured to move the first distal end 40 towards the second distal end 48. core Ln / zznz / E / YiAi The first body part 4 has a first main recess 64 on the outer surface 42 and the second body part 10 has a second main recess 66 on the outer surface 50. The first main recess 64 and the second main recess 66 are part of a locking mechanism to block, for example, the rotation of the first body part 4 relative to the second body part 10 when the drug delivery device 2 is in the first state by the arrangement of a first locking element in the first main recess 64 and the second main recess 66. Figure 2 shows a cross-sectional side view of the drug delivery device 2. The first connecting part 36 / first needle 37 extends along the first connecting axis X_1 perpendicular to the central axis A. The second connecting part 44 / second needle 45 extends along the second connecting axis X_2 perpendicular to the central axis A. The first needle 37 optionally comprises a first compartment 68 configured to accommodate an active drug substance. The first compartment 68 is optionally formed as a through-hole or cavity in the first needle 37. The second needle 45 optionally comprises a second compartment 69 configured to accommodate an active drug substance. The second compartment 69 is optionally formed as a through-hole or cavity in the second needle 45. Figure 3 shows the drug delivery device 2 in a first state. The drug delivery device comprises a locking mechanism indicated by a dotted oval 70 comprising a first main recess 64, a second main recess 66, and a first locking element 72 disposed in the first main recess 64 and the second main recess 66. The first locking element 72 is capable of preventing rotational movement of the first body part 4 and the second body part 10 relative to each other, thus maintaining a static relationship between body parts 4 and 10. The first locking element 72 may be in the form of a degradable material, such as a sugary substance, wherein contact with gastrointestinal fluids leads to the degradation of the material of the first locking element 72.When the rotational force applied to body parts 4, 10 via elastic element 16A exceeds the static force of the first locking element 72 (degraded), the first locking element 72 will release body parts 4, 10 and allow elastic element 16A to discharge its stored energy, causing the rotation of the first body part 4 with respect to the second body part 10 in a second state of the drug delivery device. Figure 4 shows the drug delivery device 2, wherein the first locking element 72 has degraded or dissolved and the second body part 10 has rotated in direction C with respect to the first body part 4. Therefore, the second connecting element 44, second distal end 48, has moved from a second primary position in the first state, as in Figure 3, to a second secondary position seen in Figure 4, via the rotational force (torque) applied to body parts 4, 10 from within the internal volume 26. During the rotation of the first body part 4 relative to the second body part 10, the actuator mechanism has moved the first distal end 40 toward the second distal end 48. Figures 5 and 6 show the drug delivery device 2 seen in Figure 4 from a side view and a front view, where it can be seen that the connecting elements 36, 44 have passed through an axis D, which can be seen, for example, as a plane that includes both the central axis A and the axis D. When the connecting elements 36, 44 pass through the imaginary plane (seen as axis D), the distal ends of the connecting elements and the opposing force applied in direction B for the first connecting part 36 and direction C for the second connecting part 44 can ensure that the distal ends can grasp a surface area and penetrate or grip the surface of the biological tissue.When the drug delivery device 2 is, for example, inside the intestine, the intestine will push the device to at least a surface area of ​​biological tissue, such that the force applied to the attachment parts will not push the device away from the surface, since the opposing surface will keep the device close to it. If the device does not initially grip, the actuator mechanism may have sufficient force for a plurality of rotations, such that when the attachment parts are close again, they will again attempt to grip the surface and fix the drug delivery device in relation to the biological tissue. Figure 7 shows the drug delivery device 2 in its second state, after attachment to body tissue 74, such as the stomach or intestinal wall. Rotation of the first body part 4 relative to the second body part 10 and movement of the first distal end 40 toward the second distal end 48 have resulted in the distal ends 40 and 48 penetrating the body tissue 74. The remaining elastic force of the actuator mechanism holds the attachment parts 36 and 44 within the body tissue 74. Thus, the drug delivery device 2 is attached to the body tissue, and the active drug substance can be released from compartments 68 and 69 and / or via opening 56, for example, to reach the bloodstream via the blood vessels of body tissue 74. Figure 8 shows an exemplary pharmaceutical composition 100 comprising a drug delivery device 2, wherein the drug delivery device 2 is encapsulated in a housing 76 optionally made of soluble material. The pharmaceutical composition 100 comprises the active drug ingredient disposed in the first compartment 68 and / or second compartment 69. The housing 76 can enclose the drug delivery device 2 to facilitate swallowing. The soluble housing 76 can dissolve within the gastrointestinal tract, and the drug delivery device 2 cannot be attached or joined until the housing 76 dissolves. Such housings are known in the art in the form of drug capsules, wherein the drug capsule material can be, for example, a gelatin, similar to hard drug capsule shells known in the art.In one or more exemplary pharmaceutical compositions, the drug delivery device may be coated with a coating. Figure 9 shows an exploded view of an exemplary drug delivery device according to the present description. The drug delivery device 2A has a central shaft A and comprises a first two-part body part 4 comprising the first main body part 4A and the first secondary body part 4B. The drug delivery device 2A comprises a first connecting part 36 comprising a first base 36A and a first needle 37 attached to the first base 36A. The first connecting part 36 has a first distal end 40 and is rotationally connected to the first body part 4 via a first connecting connection formed by the first cylindrical base 36A and a corresponding cylindrical cavity in the first body part 4. The first connecting connection has a first axis of rotation X_R_1.Therefore, the first joining part 36 is configured to rotate around the first axis of rotation relative to the first body part 4. The first axis of rotation X_R_1 is parallel to the central axis A. The drug delivery device 2A comprises a two-part second body part 10 comprising a main second body part 10A and a secondary second body part 10B. The drug delivery device 2A comprises a second connecting part 44 comprising a second base 44A and a second needle 45 attached to the second base 44A. The second connecting part 44 has a second distal end 48 and is optionally rotatably connected to the second body part 10 via a second connecting connection formed by the second cylindrical base 44A and a corresponding cylindrical cavity in the second body part 10. The second connecting part has a second axis of rotation X_R_2. Therefore, the second connecting part 44 is configured to rotate about the first axis of rotation relative to the second body part 4. The second axis of rotation X_R_2 is parallel to the central axis A. The drug delivery device 2A comprises a frame part 7 8 formed as a shaft or stem element, to which different parts are attached, such as the first body part and / or the second body part, for example, fixedly or rotatably attached to the frame part 78. The drug delivery device 2A comprises an actuator mechanism 16 comprising an elastic part 16A configured to move the first distal end 40 towards the second distal end 48 by rotating the first body part 4 relative to the second body part 10. Now, with reference to Figure 10, the first connecting part 36 is configured to rotate about the first axis of rotation relative to the first body part 4 to move the first distal end 40 from a first primary position, for example, in the first state, with a first primary radial distance from the central axis A of the delivery device 2A, to a first secondary position (shown in Figure 10) with a first secondary radial distance from the central axis A, wherein the first secondary radial distance is larger, such as at least 2 mm larger than the first primary radial distance. The first body 4 comprises a first primary recess 64 that accommodates the first connecting part 36 or at least portions thereof, for example, in the first state. The actuator mechanism 16 is optionally configured to move the first distal end from the first primary position to the first secondary position.In the first secondary position, the first part of union 36. The first connecting part 36 is configured to rotate about the first axis of rotation relative to the first body part 4 to move the first distal end from a first primary angular position to a first secondary angular position (shown in Figure 10) with respect to a first proximal end of the first connecting part. In the illustrated drug delivery device 2A, the angle between the first primary angular position and the first secondary angular position is greater than 10° and even greater than 30°, such as in the range of 35° to 85°. The actuator mechanism 16 is optionally configured to move the first distal end from the first primary angular position to the first secondary angular position. The second connecting part 44 is configured to rotate about the second axis of rotation relative to the second body part 10 to move the second distal end 48 from a second primary position, for example, in the first state, with a second primary radial distance from the central axis A of the delivery device 2A, to a second secondary position (shown in Figure 10) with a second secondary radial distance from the central axis A, wherein the second secondary radial distance is greater, such as at least 2 mm greater, than the second primary radial distance. The second body 10 comprises a second primary recess 66 that accommodates the second connecting part 44 or at least portions thereof, for example, in the first state. The actuator mechanism 16 is optionally configured to move the second distal end from the second primary position to the second secondary position. The second connecting part 44 is configured to rotate about the second axis of rotation relative to the second body part 10 to move the second distal end from a second primary angular position to a second secondary angular position (shown in Figure 10) with respect to a second proximal end of the second connecting part. In the illustrated drug delivery device 2A, the angle between the second primary angular position and the second secondary angular position is greater than 10° and even greater than 30°, as in the core Ln / zznz / E / YiAi range of 35° to 85°. The actuator mechanism 16 is optionally configured to move the second distal end from the second primary angular position to the second secondary angular position. Figures 11A-11D show a schematic view of drug delivery devices 2, 2A, 2B, and 2C, where the first connecting part 36 and the second connecting part 44 are in different positions in the second state of the drug delivery device. The first connecting part 36 has a first connecting axis X_1, and the second connecting part 44 has a second connecting axis X_2. When the first connecting part 36 and the second connecting part 44 are in contact with a plane containing the central axis A and the plane axis D, the angle α between the first connecting axis X_1 and the second connecting axis X_2 can be in the range of 5° to 75°, such as in the range of 20° to 60°. The size of the angle can increase or decrease with the distance between the central axis and the connecting axes X_1 and X_2, or when the length of the connecting elements 36 and 44 is changed. However, angle α ensures that in the transition from the position shown in Figure 11A to the position shown in Figure 11C, the biological tissue can become trapped between the two joining parts 36, 44 and if the joining parts penetrate, the greater rotation towards the position shown in Figure 11C. Figure 11D shows that the drug delivery device 2 is pulled closer to a tissue surface that can be caught by the attachment parts, using elastic force. Figure 12 shows an example drug delivery device 2B in a first state, and Figure 13 shows the drug delivery device 2B in a second state. In the first state, the first connecting part 36 with the first needle 37 is optionally arranged within the first body part 4 and / or with the first distal end in a first primary position with a first primary radial distance to the central axis. The first primary radial distance may be less than 10 mm, such as less than 8 mm or even less than 5 mm. In the first state, the first distal end 40 is optionally arranged within the first body part 4. In the first state, the second connecting part 44 with the second needle 45 is optionally arranged within the second body part 10 and / or with the second distal end in a second primary position with a second primary radial distance to the central axis. The second primary radial distance may be less than 10 mm, such as less than 8 mm or even less than 5 mm. In the first state, the second distal end 48 is optionally arranged within the second body part 10. The arrangement of the connecting part(s) / end or 101 distal ends within the body part or parts facilitates or allows for smooth oral administration. In the second state, the first distal end 40 has been ejected from the first body part 4 through the first opening 80 in the first body part 4 to be in a first secondary position with a first secondary radial distance to the central axis. The first secondary radial distance is greater than the first primary radial distance and may be greater than 5 mm, such as greater than 6 mm or greater than 8 mm. In the second state, the second distal end 48 has been ejected from the second body part 10 through the second opening 82 in the second body part 10 to be in a second secondary position with a second secondary radial distance to the central axis. The second secondary radial distance is greater than the second primary radial distance and can be greater than 5 mm, such as greater than 6 mm or greater than 8 mm. In the second state of the drug delivery device 2B, as shown in Figure 13, the actuator mechanism (not shown) rotates the first body part 4 relative to the second body part 10 and, optionally, relative to the frame part 78 about the central axis A to move the first distal end 40 toward the second distal end 48. The actuator mechanism can be configured to rotate the second body part core Ln / zznz / E / YiAi 102 in relation to frame part 78 around central axis A. Figure 14 shows an example drug delivery device 2C in a first state, and Figure 15 shows the drug delivery device 2C in a second state. In the first state, the first connecting part 36 with the first needle 37 is arranged within the first main recess 64 and the second main recess 66 and locked by the first locking element 72. Therefore, the first connecting part 36 and the first locking element 72 prevent rotation of the first body part and the second body part. The second connecting part 44 is similarly arranged within the first secondary recess of the first body part and the second secondary recess of the second body part on the opposite side and locked by the second locking element.In the first state, the first joint axis of the first joint part 36 is substantially parallel to the central axis and the second joint axis of the second joint part is substantially parallel to the central axis. The first blocking element 72 dissolves in the gastrointestinal tract and the first distal end 40 moves from its first primary position in the first state (Figure 14) to a first secondary position in the second state (Figure 15) by rotation around a first rotation axis X_R_1 perpendicular to the central axis A. 103 Likewise, the second blocking element dissolves in the gastrointestinal tract and the second distal end 48 moves from its second primary position in the first state (Figure 14) to a second secondary position in the second state (Figure 15) by rotation around a second axis of rotation (not shown) perpendicular to the central axis A. The angle between the first primary direction in the first state and the first secondary direction in the second state is at least 30°, such as 45° or more. The first secondary direction of the first joining part may be perpendicular or substantially perpendicular to the central axis. The angle between the second principal direction in the first state and the second secondary direction in the second state is at least 30°, such as 45° or more. The second secondary direction of the second joining part may be perpendicular or substantially perpendicular to the central axis A. In the second state, the actuator mechanism moves the first distal end 40 toward the second distal end 48 by rotating the first body part 4 relative to the second body part 10, thereby reducing the angle between the first secondary direction and the second secondary direction. In the first state, the first connecting part 36 with the first needle 37 is arranged with the first distal end in a first primary position with a first primary radial distance to the central axis. The first primary radial distance 104 may be less than 10 mm, such as in the range of 3 mm to 8 mm. In the first state, the second connecting part 44 with the second needle 45 is arranged with the second distal end in a second primary position with a second primary radial distance to the central axis. The second primary radial distance may be less than 10 mm, such as in the range of 3 mm to 8 mm. In the second state, the connecting parts 36, 44 have been unfolded from the body parts 4, 10 so that the distal ends 40, 48 are in a respective first secondary position with a first secondary radial distance to the central axis and a second secondary position with a second secondary radial distance to the central axis. The first secondary radial distance is greater than the first primary radial distance and may be greater than 5 mm, such as greater than 6 mm or greater than 8 mm. The second secondary radial distance is greater than the second primary radial distance and may be greater than 5 mm, such as greater than 6 mm or greater than 8 mm. In the second state of the drug delivery device 2C, as shown in Figure 15, the actuator mechanism (not shown) rotates the first body part 4 relative to the second body part 10 around central axis A to move the first distal end 40 towards the second distal end 48. core Ln / zznz / E / YiAi 105 Figure 16 shows an example 2D drug delivery device, and Figure 17 shows an exploded view of the same 2D drug delivery device. The 2D drug delivery device may include any and / or all of the features discussed above with respect to Figures 1-15 unless otherwise indicated. As shown, the 2D drug delivery device may include a first body recess 108 configured to allow rotation of the first joining part 104. Additionally, the 2D drug delivery device may include a second body recess (not shown) configured to allow rotation of the second joining part 106. The first joining part 104 and the second joining part 106 may both include a joint 116, thereby forming a bent needle or tip. This may allow for easier tissue penetration. Furthermore, as shown, the 2D drug delivery system may include a first locking band 102. The first locking band 102 can prevent rotation of the first body part 4 with respect to the second body part 10. The first locking band 102 can be used in place of a locking element 72. Alternatively, the first locking band 102 can act as a first 106 cover band 103 and use in conjunction with a locking element 72. Specifically, the first locking band 102 may include a plurality of locking protrusions 112. The locking protrusions 112 may fit within the coupling features 114 of the 2D drug delivery system. Once coupled, the locking protrusions 112 prevent rotation of the first body part 4 and the second body part 10. The first locking band 112 may then dissolve to permit rotation. Modalities of the drug delivery device described herein were used in animal studies that yielded the following experimental results. These experimental results illustrate the success of one or more exemplary drug delivery devices in real-world use. Successful attachment (e.g., binding) in the experimental results can be defined as being attached for at least 4 hours. Figure 18 shows X-ray images of the drug delivery device that has been attached (e.g., joined, connected) via one or more of the first or second joining part. Figure 19 shows X-ray images and additional data regarding modalities of the described drug delivery device that has core junction parts Ln / zznz / E / YiAi 107 biodegradable. As shown, the first or second bonding part degraded in each of the tested animals, allowing for the recovery of the drug delivery device. Furthermore, as described, the drug delivery device can remain attached within a body for more than 24 or 48 hours. All tests of the drug delivery device adhered to the tissue of the analyzed animal. Figure 20 shows additional X-ray images and data regarding modalities of the described drug delivery device that have a non-biodegradable bonding component. This data provides further evidence of the drug delivery device's success, as it remained attached for at least 24 or 48 hours. All but one of the tested drug delivery devices adhered to the animal tissue. Figure 21 summarizes the data obtained using the described drug delivery device modalities. Figure 22 illustrates a study of the attachment of the described drug delivery devices. As shown, all devices were confirmed to attach within the tissue of the tested animal. Furthermore, the devices remained attached to the tissue for at least 5 hours and 30 minutes. 108 Figure 23 illustrates pharmacodynamic data using at least one of the drug delivery devices described above. As shown, the data indicate a drop in blood glucose after dosing 4 international units of insulin. Therefore, Figure 23 illustrates changes in blood glucose levels upon hooking up and delivering an active drug substance, for example, insulin. Devices, methods, and administration compositions are also described according to any of the following elements. Item 1. A drug delivery device having a central shaft, the drug delivery device comprises: a first part of the body; a first joining part attached to the first body part and having a first distal end; a second joining part having a second distal end and an actuator mechanism configured to move the first distal end towards the second distal end. Point 2. The drug delivery device according to point 1, the drug delivery device comprising a second body part, wherein the second connecting part is attached to the second body part and 109 The actuator mechanism is configured to rotate the first body part relative to the second body part around a main axis of the drug delivery device. Point 3. The drug delivery device according to point 2, wherein the actuator mechanism comprises an elastic part configured to apply force to the first body part and / or the second body part. Point 4. The drug delivery device according to point 3, wherein a first part of the elastic part is connected to the first body part and a second part of the elastic part is connected to the second body part. Item 5. The drug delivery device according to any of items 1 to 4, wherein the first attachment part extends in a direction away from the first body part. Point 6. The drug delivery device according to any of points 1 to 5 depending on point 2, wherein the second part of the attachment extends in a direction away from the second part of the body. Point 7. The drug delivery device according to any of points 1-6 depending on point 2, wherein the first joining part has a first joining axis and wherein the distance between the first joining axis 110 and the primary shaft is greater than 0.5 mm. Point 8. The drug delivery device according to any of points 1-7 depending on point 2, wherein the second joining part has a second joining axis and wherein the distance between the second joining axis and the primary axis is greater than 0.5 mm. Item 9. The drug delivery device according to any of items 1 to 8 depending on item 2, wherein the first body part is configured to rotate in a first direction and the second body part is configured to rotate in a second direction opposite to the first direction. Item 10. The drug delivery device according to any of items 1-9, wherein the first distal end of the first joining part and / or the second distal end of the second joining part is provided with a tip configured to penetrate biological tissue. Item 11. The drug delivery device according to any of items 1-10, wherein the first distal end of the first joining part and / or the second distal end of the second joining part is provided with a gripping portion configured to hold a biological tissue. Point 12. The drug delivery device according to any of points 1-11, wherein the drug delivery device comprises a first 111 compartment, the drug delivery device is configured to deliver an active drug substance from the first compartment to the surroundings of the drug delivery device. Point 13. The drug delivery device according to any of points 1-12 depending on point 2, wherein the first joining part and the second joining part form an angle when the first distal end and the second distal end are in a plane that includes the primary axis. Point 14. The drug delivery device according to any of points 1-13 depending on point 2, wherein the drug delivery device has a first state in which the first body part and the second body part are rotatably stationary with respect to each other and a second state in which the first body part and the second body part are rotatably movable with respect to each other. Point 15. The drug delivery device according to any of points 1 to 14 depending on point 3, wherein the drug delivery device has a first state in which the elastic part has a constant elastic force load and a second state in which the elastic part releases at least partially the elastic force load. core Ln / zznz / E / YiAi 115 It will be evident to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the claimed invention. Accordingly, the description and figures should be considered in an illustrative and not restrictive sense. The claimed invention is intended to cover all alternatives, modifications, and equivalents. List of References 2, 2A, 2B, 2C, 2D Core Drug Delivery Device Ln / zznz / E / YiAi First Body Part 4A first part of main body 4B first part of secondary body 6 first end of the first part of body 8 second end of the first part of body 10 second part of body 10A second part of main body 10B second part of secondary body 12 ] first end of second part of body second end of second part of body actuator mechanism 16A resilient or elastic part first part of resilient or elastic part second part of elastic part outer periphery of the spiral torsion spring 116 central part of the spiral torsion spring internal volume internal surface first coupling part first coupling part second coupling part groove first joining part 36A first base first needle first proximal end of first joining part first distal end of first joining part external surface of first body part second joining part second needle second proximal end of second joining part second distal end of second joining part external surface of second body part sharp point opening first primary rebate in first body part second primary rebate in second body part first compartment second compartment locking mechanism core Ln / zznz / E / YiAi 117 72 first locking element 5 74 76 78 80 body tissue housing frame part first opening in first body part 82 second opening in second body part 10 15 100 102 103 104 106 108 112 114 116 pharmaceutical composition first locking band first cover band first joining part second joining part first body recess locking protrusion coupling feature joint A central axis / primary axis B direction of rotation C direction of rotation D axis of plane X_1 first joining axis X_R_1 first axis of rotation X 2 second joining axis X_R_2 second axis of rotation at angle It is noted that with regard to this date, the 118 The best method known to the applicant for carrying out the aforementioned invention is the conventional method for manufacturing the objects to which it refers. It is hereby stated that, as of this date, the best method known to the applicant for putting the aforementioned invention into practice is the one that is clear from the present description of the invention.

Claims

1. A drug delivery device having a central shaft, characterized in that it comprises: a first body part; a first connecting part attached to the first body part and having a first distal end; a second connecting part having a second distal end; and an actuator mechanism configured to move the first distal end toward the second distal end.

2. The drug delivery device according to claim 1, characterized in that it comprises a second body part, wherein the second connecting part is attached to the second body part and the actuator mechanism is configured to rotate the first body part relative to the second body part about a main axis of the drug delivery device.

3. The drug delivery device according to claim 2, characterized in that the actuator mechanism comprises an elastic part configured to apply force to the first body part and / or the second body part.

4. The drug delivery device according to claim 3, characterized in that a first part of the elastic part is connected to the first body part and a second part of the elastic part is connected to the second body part.

5. The drug delivery device according to any of claims 1-4, characterized in that the first joining part extends in a direction away from the first body part.

6. The drug delivery device according to any of claims 1-5 when dependent on claim 2, characterized in that the second joining part extends in a direction away from the second body part.

7. The drug delivery device according to any of claims 1-6 when dependent on claim 2, characterized in that the first joining part has a first joining axis and wherein the distance between the first joining axis and the primary axis is greater than 0.5 mm.

8. The drug delivery device according to any of claims 1-7 when dependent on claim 2, characterized in that the second joining part has a second joining axis and wherein the distance between the second joining axis and the main axis is greater than 0.5 mm.

9. The drug delivery device according to any of claims 1-8 when dependent on claim 2, characterized in that the first body part is configured to rotate in a first direction and the second body part is configured to rotate in a second direction opposite to the first direction.

10. The drug delivery device according to any of claims 1-9, characterized in that the first distal end of the first joining part and / or the second distal end of the second joining part is provided with a tip configured to penetrate a biological tissue.

11. The drug delivery device according to any of claims 1-10, characterized in that the first distal end of the first joining part and / or the second distal end of the second joining part are provided with a gripping portion configured to hold a biological tissue.

12. The drug delivery device according to any of claims 1-11, characterized in that it comprises a first compartment, the drug delivery device being configured to deliver an active pharmacological substance from the first compartment to the surroundings of the drug delivery device.

13. The drug delivery device according to any of claims 1-12 when dependent on claim 2, characterized in that the first joining part and the second joining part form an angle, when the first distal end and the second distal end are in a plane that includes the main axis.

14. The drug delivery device according to any of claims 1-13 when dependent on claim 2, characterized in that it has a first state, wherein the first body part and the second body part are rotatably stationary with respect to each other and a second state, wherein the first body part and the second body part are rotatably movable with respect to each other.

15. The drug delivery device according to any of claims 1-14 when dependent on claim 3, characterized in that it has a first state, wherein the elastic part has a constant elastic force load and a second state, wherein the elastic part at least partially releases the resilient force load.

16. The drug delivery device according to any of claims 1-15, characterized in that the actuator mechanism is configured 123 to move the first distal end from a first primary position with a first primary radial distance from the central axis of the delivery device to a first secondary position with a first secondary radial distance from the central axis, wherein the first secondary radial distance is greater than the first primary radial distance.

17. The drug delivery device according to any of claims 1-16, characterized in that the actuator mechanism is configured to move the first distal end from a first primary angular position to a first secondary angular position relative to a first proximal end of a first joining part, wherein the angle between the first primary angular position and the first secondary angular position is greater than 10 degrees.

18. The drug delivery device according to any of the preceding claims, characterized in that it comprises a locking mechanism configured to lock the first body part with respect to the second body part in a first state of the drug delivery device.

19. The drug delivery device according to claim 18, characterized in that the locking mechanism is configured to lock the first 124 binding part in a first principal position when the drug delivery device is in the first state.

20. The drug delivery device according to any of claims 1-19 when dependent on claim 2, characterized in that the first connecting part is rotatably attached to the first body part and configured to rotate about a first axis of rotation perpendicular or parallel to the main axis.

21. The drug delivery device according to any of claims 1-20 when dependent on claim 2, characterized in that the second connecting part is rotatably attached to the second body part and configured to rotate about a second axis of rotation perpendicular or parallel to the main axis.

22. A pharmaceutical composition, characterized in that it comprises the drug delivery device according to any of claims 1-20 and an active drug substance.

Images